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Abstract 
This thesis addresses some of the challenges that clinicians face in the course of treatment 
of brain tumors. Glioblastoma multiforme (GBM, grade IV) is the most malignant form 
of primary brain tumor and recurrence following treatment is common.  Non-invasive 
imaging is an important component of brain tumor treatment planning and monitoring.  
Unfortunately, tumor recurrence and radiation injury (RI) in patients with GBM have 
similar appearances on follow-up conventional magnetic resonance imaging (MRI), 
making it difficult to choose the most appropriate treatment plan.  Brain metastases which 
are secondary brain tumors are common in patients with systemic cancer.  Differentiating 
between GBM and metastatic tumor is also difficult with conventional MRI, but is 
essential for guiding surgical and radiotherapy treatment. Therefore, the overall goal of 
this thesis is to develop imaging methods that improve brain tumor detection. 
The first objective was to develop a method to discriminate between GBM tumor 
recurrences and RI using a multiparametric characterization of the tissue incorporating 
conventional MRI signal intensities (T2-weighted (T2w) and fluid attenuated inversion 
recovery (FLAIR)) and diffusion tensor imaging parameters (fractional anisotropy (FA) 
and radial diffusivity (RD)). In the RI region there were significant correlations between 
FA and RD as well as between T2w and FLAIR signal intensities.  No such correlations 
were observed in the tumor region. These correlations may aid in differentiating between 
tumor recurrence and RI. 
The second objective was to differentiate between GBM and metastasis (MET); the two 
most common types of brain tumors.  Both exhibit similar radiologic appearance on 
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routine MR imaging but require different treatment strategies. The goal of this study 
was to investigate whether texture based image analysis of routine MR images (contrast-
enhanced T1-weighted images) would provide quantitative information that could be 
used to differentiate between GBM and MET. Our results demonstrate that first-order 
texture feature of standard deviation and second-order texture features of entropy, inertia, 
homogeneity, and energy show significant differences between the two groups. Receiver 
operating characteristic (ROC) curve analysis showed that combining first- and second-
order features increased the predictive accuracy in differentiating between GBM and 
MET.  
Finally, helical tomotherapy (HT) is a type of radiation delivery technique that allows for 
a radiosurgery-type simultaneous infield boost (SIB) of multiple brain metastases, 
synchronously with whole brain radiation therapy (WBRT). However, some patients’ 
tumors may not respond to HT type WBRT+SIB. The goal of our study was to 
investigate whether quantitative measurements of tumor size and appearance on magnetic 
resonance imaging (MRI) scans acquired prior to HT type WBRT+SIB treatment could 
be used to differentiate responder and non-responder patient groups. Our results 
demonstrated that smaller size lesions may respond better to this type of radiation 
therapy. Measures of appearance provided limited added value over measures of size for 
response prediction. Quantitative measurements of rim enhancement and core necrosis 
performed separately did not provide additional predictive value. 
In summary, our correlation based method for differentiating tumor from RI, 
differentiating GBM and MET using quantitative texture features, and correctly selecting 
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patients who will respond to HT type radiation treatment may be used to better plan 
patient treatment. 
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1 Introduction 
Accurate discrimination of tumor from radiation injured tissues and differentiation of 
tumor types and grades using noninvasive imaging is essential for guiding surgical and 
radiotherapy treatments. This thesis describes the use of multiparametric imaging and 
image processing techniques to characterize brain tumors.  The long-term goal of these 
methods is to help select appropriate treatment and assess treatment response in patients 
with brain tumor.  
This chapter introduces the imaging and image processing techniques upon which the 
following chapters are based. Chapter 2 describes the application of multiparametric 
imaging in an attempt to improve the detection of brain tumor recurrence following 
treatment. Chapter 3 describes the use of texture based analysis in differentiating 
enhancing lesions as primary or secondary tumor types. Chapter 4 outlines the use of 
texture based image analysis for patient selection in radiation therapy.  
1.1 Brain Tumor  
A tumor is any uncontrolled growth of abnormal cells. Tumors that are located within the 
brain are called brain tumors and can be classified into two categories: primary and 
secondary brain tumors.  
Primary brain tumors can arise from the cells, the meninges (membranes around the 
brain), or neurons in the brain. Gliomas and meningiomas are the most common primary 
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brain tumors. Gliomas are thought to be derived from glial cells such as astrocytes, 
oligodendrocytes, and ependymal cells. Gliomas are classified into four grades by the 
World Health Organization (WHO) on the basis of their histologic features and 
malignancies1. Glioblastomas are considered grade IV; the most aggressive and 
malignant type of brain tumor.  
Secondary brain tumors are referred to as metastases. They do not initiate in the brain, 
but rather metastases occurs when cancer cells break away from a primary tumor site 
elsewhere in the body and travel to the brain through the blood system.  
1.1.1 Primary Brain Tumor: Glioblastoma Multiforme 
Glioblastoma multiforme (GBM) is the most lethal and aggressive form of primary brain 
tumor. It is a grade IV type of brain tumor. Median survival for patients with 
glioblastoma is 12-15 months2. GBM is derived from the malignant transformation of 
glial cells3. Despite recent advances in radiation, chemotherapy, surgical techniques, and 
newer investigational drugs, GBM has a poor prognosis. Medical imaging plays an 
important role in the diagnosis of GBM. Typically post-contrast magnetic resonance 
(MR) imaging is used for diagnosis followed by biopsy for pathological validation. GBM 
often appear as ring-enhancing lesions on post-contrast MR images (Figure 1.1)3, 4. 
Treatment options for patients with GBM are determined by tumor size, location, and the 
associated symptoms. The current standard of care for patients with GBM is surgical 
resection of the tumor followed by radiation therapy and concomitant and adjuvant 
temozolomide chemotherapy. This approach has been shown to standardize treatment and 
prolong survival for patients5.  Radiation therapy damages the genetic material (DNA) 
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within tumor cells and limits their ability to successfully reproduce6, 7. Tumor cells are 
less able to repair DNA than healthy cells. With each subsequent radiation dose, the 
cumulative effect of unrepaired DNA strand breaks initiates apoptosis (cell death) in 
these tumor cells6, 7. 
Radiation injury (RI) is an undesirable but unavoidable side effect of radiation treatment. 
Radiation injury is characterized by extensive necrosis due to small artery injury and 
direct damage to oligodendroglia8. The incidence of radiation injury depends on the total 
radiation dose and the rate of delivery9. Concomitant chemotherapy enhances radiation 
injury. RI appears as enhancing lesions on MR imaging. Since GBM is a high grade 
tumor, recurrences are common even after treatment, and these recurrences appear as 
hyperintense regions on post-contrast MR images.  
 
Figure 1.1 Post-contrast T1-weighted image of patient with glioblastoma. The tumor 
appears to have a necrotic core and enhancing rim. 
The presence of enhancing lesions after chemo-radiation therapy may represent either 
tumor recurrence or radiation induced injury or both 10, 11. Differentiating between tumor 
recurrence and RI regions can be difficult with conventional MR imaging 12, however it 
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is very important to differentiate these two entities since the treatment options and 
prognoses for each are considerably different. 
There have been numerous attempts to differentiate tumor recurrences from RI using 
conventional morphologic imaging as well as various functional imaging techniques such 
as CT perfusion, MR perfusion, diffusion weighted imaging, MR spectroscopy, single-
photon emission computed tomography and positron emission tomography12-29. Table 1.1 
provides a partial list of studies that have used various techniques to differentiate tumor 
recurrence from RI.  
Table 1.1  Techniques used for differentiating tumor recurrence from radiation 
injury12-29 
Technique Reference Parameter 
Diffusion Hein et al. Apparent diffusion coefficient ratios 
 Kashirmura et al. Fractional anisotropy 
 Asai et al. Apparent diffusion coefficient 
 Sundgren et al. Fractional anisotropy 
 Xu et al. Fractional anisotropy 
 Zeng et al. Apparent diffusion coefficient 
   
Perfusion Barajas et al. Cerebral blood volume 
 Jain et al. Cerebral blood flow 
 Jain et al. Cerebral blood volume 
 Bobek-Billewicz Cerebral blood volume 
 Fisher-stevens et al. Permeability  
   
MRS Rabinov et al. Choline / Creatine 
 Zeng et al. Choline / Creatine 
 Zeng et al. Choline / N-Acetyl aspartate 
 Rock et al. Choline / Creatine 
 Rock et al. Choline / N-Acetyl aspartate 
   
PET Langleben et al.  Fluorodeoxy glucose uptake 
 Tsuyuguchi et al. 11C-Methionine uptake 
   
SPECT Schwartz et al.  201Thallium uptake 
 Samnick et al. 123 Iodine uptake 
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All of the above techniques have shown some promise but none of them have been able 
to convincingly differentiate radiation injury from tumor recurrence. FDG-PET and 
dynamic contrast enhanced CT have shown better sensitivity and accuracy compared to 
other techniques. However, with the limited availability of PET scanners and the risks 
associated with radiation exposure from CT, the search for an accessible and reliable 
technique continues with biopsy of the affected tissue still considered the gold standard. 
1.1.2 Secondary Brain Tumor: Metastasis 
Brain metastasis is common among patients with systemic cancer. They are a significant 
public health issue, with 20–40% of patients with solid tumors subsequently developing 
symptomatic brain metastases30. Approximately 150,000 brain metastases are diagnosed 
annually in the United States. Brain metastasis (MET) is thought to occur when the 
primary tumor acquires the ability to migrate away from the primary site and travels to 
the brain. The most common origins of brain metastasis are from breast cancer, 
melanoma and lung cancer. Metastasis often causes severe neurological symptoms that 
significantly impair quality of life. With recent improvements in diagnostic imaging and 
increasing patient survival due to improved systemic cancer control, the incidence of 
intracranial metastatic disease is projected to rise31. Imaging is the most important 
diagnostic modality for brain metastasis. Metastasis appears as an enhancing rim with 
necrotic core on a post-contrast MRI (Figure 1.2). The management of brain metastasis 
initially involves treating the symptoms using corticosteroids, anticonvulsants to reduce 
peritumoral edema and prevent recurrent seizures and surgical resection for debulking 
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followed by therapeutic approaches of whole brain radiotherapy (WBRT), stereotactic 
radiosurgery (SRS), and/or chemotherapy.  
 
 
Figure 1.2 Post-contrast T1-weighted image of patient with metastasis. The tumor 
has a necrotic core and enhancing rim. 
 
Whole brain radiotherapy (WBRT) is the most commonly used treatment for patients 
with brain metastasis. It involves delivering a uniform dose of radiation from a linear 
accelerator to the entire brain while the patient head is immobilized to minimize 
movement during treatment32. A perforated thermoplastic mask that is shaped to conform 
to the individual patient’s facial features is used to immobilize the patient’s head during 
treatment. Whole brain radiation therapy (WBRT) delivers an even dose of radiation to 
the entire brain. Figure 1.3 shows WBRT radiation dose planning image. It can be used to 
treat small undetectable tumors, large tumors that may be developing in different areas of 
the brain and tumors that are deep in the brain which are inaccessible to surgery. Since 
radiation is delivered to the entire brain WBRT has side effects that include nausea, 
vomiting, headache, fever, fatigue and possible worsening of neurologic symptoms. 
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There is also a risk of memory loss or dementia. WBRT typically improves symptoms, 
but longer-term survivors may develop neurocognitive deficits33, 34. 
 
 
Figure 1.3 Radiation dose planning image for WBRT (yellow=100% of the dose, 
orange =98%, red=95%, green = 80%, blue =70%). A traditional WBRT delivers 
30-60 Gy in 10-15 fractions. 
 
Stereotactic radiosurgery (SRS) is a more targeted form of radiation therapy in which a 
higher dose of radiation is delivered to the tumor in a single treatment session. Figure 1.4 
shows a typical SRS radiation dose planning image. The radiation beam is concentrated 
on a small region of the parietal lobe. Typically multiple radiation beams are delivered to 
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the tumor from many different angles using special computer planning. A stereotactic 
head frame is used to keep the patient’s head completely still during the procedure. 
Because this form of radiation targets the tumor more precisely, it is less likely to hurt 
healthy tissue. Generally, SRS may be used to treat patients with up to three lesions, 
although this may vary depending on the size and location of the tumors. For multiple 
lesions (>3), WBRT is usually the best option. WBRT or SRS is also an option for people 
who are not candidates for surgery.  
 
 
Figure 1.4 Radiation dose planning image for SRS (yellow=100% of the dose, 
orange =98%, red=95%, green = 80%, blue =70%). A traditional SRS would deliver 
15-20 Gy in a single fraction. 
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SRS combined with WBRT has been shown to yield superior local control, as compared 
with WBRT alone35. Since SRS involves high dose of radiation to a small region, it has a 
higher frequency of side effects related to brain tissue necrosis and edema, which can put 
pressure on surrounding healthy brain tissue. SRS also requires separate stereotactic 
localization and treatment procedures that add to the cost and patient inconvenience. In 
addition, the sequential delivery of WBRT and SRS does not allow for the integration of 
radiation delivery across both components, limiting the ability to fully optimize the 
radiation dose. 
Helical tomotherapy (HT) is a radiotherapy delivery technique that allow for 
radiosurgery-type simultaneous infield boost (SIB) treatments to be given synchronously 
with the standard WBRT dose. In HT, the treatment beam rotates about the gantry while 
the patient table is moved through the gantry, thereby creating a helical or spiral type of 
beam, hence the name helical tomotherapy. This form of delivery technique can be used 
to efficiently boost multiple brain metastases without the need for separate stereotactic 
procedures36, 37. The ability to incorporate this boost contribution with larger field 
volumes as part of the treatment planning optimization process is advantageous over 
sequential WBRT and SRS. It has also been shown that HT type WBRT+SIB dose 
distribution and lesion conformity is comparable to SRS alone38. This type of radiation 
delivery is beneficial for patients with multiple lesions and lesions that are in close 
proximity to sensitive organs. It is also useful for patients who cannot be immobilized 
due to claustrophobia, obesity or physical impairment39.  
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Figure 1.5 Radiation dose planning image for HT, illustrating a whole brain 
radiation plan with integrated high-dose boost (purple) to a metastatic lesion. The 
patient underwent HT with 30 Gy WBRT and 60 Gy SIB in 10 fractions. 
 
 
HT type WBRT+SIB has potential advantages compared to surgery and SRS but it is not 
appropriate for every patient. Some patients’ tumors may not respond to simultaneous 
WBRT+SIB, and are more appropriately treated with radiosurgery or conventional 
surgery.  
1.2 Treatment Assessment 
Treatment assessment is critical for measuring tumor response to therapy. The 
development of contrast-enhanced CT and MR imaging has allowed radiologists to assess 
therapeutic response more accurately and reproducibly in patients with brain tumors. 
Imaging for treatment assessment is routinely performed at three months interval post 
chemo-radiation therapy. Advanced CT and MRI techniques are currently being used in 
research settings as response assessment tools for brain tumor patients and are based on 
detecting cellular changes, and detecting changes in metabolic and hemodynamic 
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activity40.  In clinical settings, changes in lesion size are widely used to assess tumor 
response to therapy. 
1.2.1 Response Evaluation Criteria in Solid Tumors 
The assessment of treatment response in brain tumors is based on clinical and imaging 
parameters. A number of techniques have been proposed to assess treatment response. 
The Macdonald criteria are widely used in assessing treatment response41 of glial tumors. 
These criteria involve computing the cross-sectional area of the tumor by measuring the 
longest single diameter and the longest perpendicular diameter. A 50% decrease in the 
area is considered a partial response while an 25% increase in the area is considered 
progression. As an update to the Macdonald criteria, the revised assessment in neuro-
oncology criteria42 is used for assessing disease progression and treatment response in 
GBM. 
The most common way to assess treatment response in metastasis is the anatomical based 
method known as response evaluation criteria in solid tumors (RECIST). RECIST were 
originally published in 2000 and then updated in 2009 for use as a treatment assessment 
tool in clinical oncology43, 44. RECIST are a set of guidelines that were developed to 
allow for a simplified and standardized assessment of solid tumors. They classify 
therapeutic responses in brain tumors based on a one-dimensional tumor measurement: 
the longest diameter across a contrast-enhancing lesion in the axial plane. In cases where 
multiple lesions are present, the sum of the longest diameters of up to two measurable 
lesions is obtained.  
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Table 1.2 Four categories of RECIST. 
Response Criteria: 
RECIST 1.1 
Description 
Complete Response 
(CR) 
Disappearance of all target lesions. 
 
Partial Response (PR) At least a 30% decrease in the sum of 
diameters of the target lesions, taking as reference the 
baseline sum diameters. 
 
Progressive Disease 
(PD) 
At least a 20% increase in the sum 
of diameters of target lesions, taking as reference 
the baseline sum diameters. The appearance of one or 
more new lesions is also considered progression. 
 
Stable Disease (STD) Neither sufficient shrinkage to qualify as PR nor 
sufficient progression to qualify as PD.  
 
 
The major advantage of the RECIST system is its simplicity. A single diameter 
measurement is done in the axial plane on the post-contrast images, which can be performed easily and rapidly. The technique performs comparably to more complex two-dimensional and volumetric methods of treatment assessment in brain tumor studies45, 46. 
1.3 Multiparametric Imaging 
Imaging modalities such as computed tomography (CT) and magnetic resonance imaging 
(MRI) are commonly used for diagnosis and treatment assessment. CT is often the first 
line imaging modality performed in patients with brain tumors because it is relatively 
inexpensive, minimally invasive, and widely available in clinical settings. CT is also used 
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for surgical planning and radiation treatment planning but MRI is preferred due to its 
superior soft tissue contrast. For brain tumors, imaging is routinely performed before the 
initial treatment, immediately after the treatment and at 3-6 month interval thereafter (for 
high grade brain tumor patients imaging is performed at 2-3 months intervals).  
RECIST measures tumor response to treatment based on assessment of anatomical MR 
images. RECIST requires a well-defined anatomical lesion and relies on the serial 
measurements of reduction in tumor size during treatment as the basis for response 
assessment. Treatment selection and response assessment can also be based on functional 
evaluation of CT and MR images. 
1.3.1 Perfusion CT  
Brain tumors are associated with angiogenesis and neovascularization (forming new 
blood vessels) that results in increased blood volume and permeability related to the 
immature vessels47-51. Previous studies have indicated increased microvascular 
permeability with the increase in biologic aggressiveness of tumors, while a reduction in 
permeability in response to therapy correlates with decreased tumor growth49, 50. Since 
perfusion CT (PCT) provides an in vivo marker of angiogenesis, it is widely used as both 
a diagnostic tool and as a treatment assessment tool in brain tumor imaging52, 53. 
Perfusion CT typically requires the acquisition of a baseline image without contrast 
enhancement followed by a series of images acquired as a function of time following an 
intravenous bolus injection of a conventional iodinated CT contrast material. The 
resulting temporal changes in contrast enhancement of the tissue are displayed as time–
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attenuation curves (TAC). These TACs are used to quantify a range of parameters that 
reflect the functional status of the vascular system. This approach is used to produce 
parametric maps that represent cerebral blood volume (CBV), blood flow (CBF), 
permeability (PS), mean transit time (MTT), and the size of extravascular space. Many of 
these parameters have been correlated with tumor grade, aggressiveness, and 
prognosis54, 55.   
Tissue perfusion, blood volume, mean transit time, and other vascular physiological 
parameters can be derived from dynamic CT data53, 56. The first phase of enhancement 
(Figure 1.6) can be used to evaluate blood flow, and blood volume which are generally 
increased in malignant tissues. The second phase is used to evaluate vascular 
permeability (since tumor blood vessels are abnormally permeable to the contrast agent 
used)56, 57. Deconvolution method is the most widely used analysis method for 
determination of perfusion parameters. The deconvolution operation uses a reference 
“arterial” input function that is selected most often within the anterior cerebral artery. The 
impulse residue function (IRF) is then calculated by deconvolution of the arterial and 
tissue time–attenuation curves for the tissue of interest. The IRF (Figure 1.7) is usually 
constrained in its shape to comprise a plateau followed by a single exponential decay53. 
The height of the flow scaled IRF will provide the cerebral blood flow and the area under 
the curve will determine the cerebral blood volume. Width of the IRF equals the mean 
transit time (MTT). This approach can also be used to include a measurement of capillary 
permeability by use of a distributed parameter model53.  
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Figure 1.6 A general arterial time attenuation curve showing the first and second 
phase enhancement. (HU = hounsfield units). 
 
 
 
Figure 1.7 Blood flow scaled IRF according to the Johnson and Wilson model. The 
height of the IRF is the cerebral blood flow and the area under the curve will 
determine the cerebral blood volume. Width of the IRF equals the mean transit 
time. 
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PCT provides quantitatively accurate assessment of brain perfusion. PCT measurements 
have been shown to be reproducible and have been validated against a range of reference 
methods including xenon CT and positron emission tomography (PET)58-64. PCT has 
been used to estimate tumor grade and predict response to radiation therapy in cerebral 
tumors65-67. The results of perfusion studies49, 50 have shown that CBV and PS, a measure 
of microvascular permeability, are predictive of pathologic grade and correlates with 
tumor activity. Studies utilizing perfusion techniques have used cerebral blood volume 
(CBV) values68-70 and recovered percentage of signal intensity and peak height71 (i.e. 
shape of dynamic perfusion data) to differentiate  between metastasis and GBM. 
1.3.2 MRI: T1w, T2w and FLAIR Imaging72, 73, 74 
MR imaging is an important diagnostic and treatment assessment imaging modality that 
has become essential to routine clinical brain tumor imaging due to its superior soft tissue 
contrast. In clinical MR imaging, the hydrogen nucleus (proton) is primarily used because 
it is abundantly present in the human body (70-90%) and has high detection sensitivity 
due to its high gyromagnetic ratio. Since hydrogen atoms have an odd number of protons, 
this nucleus possesses a property known as spin angular momentum. The phenomenon of 
magnetic resonance arises in atoms with odd numbers of protons. In absence of a static 
magnetic field, the protons are oriented randomly and the net macroscopic magnetic 
moment is zero. When these protons are subjected to a static magnetic field (B0), the 
magnetic moment vectors have a tendency to align in the direction of the static field 
producing a net magnetization (M0). They also exhibit precessional behavior at a well-
defined frequency due to the interaction between the static magnetic field and the 
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magnetic moment of the nucleus. The frequency of precession is proportional to the 
strength of the static magnetic field and is expressed by the Larmor Equation (equation 
1.1). 
𝑓 =  𝛾
2𝜋
 𝐵0  [1.1] 
f = Larmor frequency in Hertz 
B0 = static magnetic field strength in Tesla (T) 
γ = gyromagnetic ratio (for protons, γ = 42.57 MHz/T) 
In order to induce signal in the tissue of interest, a component of the net magnetization 
must be tilted away from its equilibrium axis (z-axis) into the transverse (x-y) plane, 
which is achieved by applying a rotating magnetic field in the transverse plane at the 
Larmor frequency using a radio frequency (RF) coil. This process is called excitation, 
and the applied magnetic field is called an RF pulse. The amplitude and duration of this 
RF pulse produces a predictable torque on the magnetization vector causing it to rotate 
away from its equilibrium position by precessing about the axis defined by the RF pulse. 
This angle of rotation away from the z-axis is also known as flip angle. The transverse 
component of the magnetization is then detected by the same RF coil. The resulting time-
varying signal is called the free induction decay (FID) and represents the basic MR 
signal. The most common excitation RF pulse is a 90o pulse that rotates the 
magnetization by 90o into the x-y plane resulting in no z-component. Eventually the net 
magnetization vector will return to its equilibrium state along the z-axis: this process is 
called relaxation. Relaxation has both longitudinal and transverse components that occur 
simultaneously but independent of each other. Longitudinal relaxation refers to recovery 
 18 
 
 
of the longitudinal magnetization along the z-axis, and is characterized by the T1 time 
constant (Figure 1.8). This is the mechanism by which protons give up their energy to the 
surrounding lattice in order to return to their equilibrium energy distribution. This process 
of relaxation is also known as spin-lattice relaxation.    
The longitudinal component of magnetization can be written as:  
𝑀𝑧(𝑡) =  𝑀0 (1 −  𝑒−𝑡𝑇1 ) [1.2] 
 
 
Figure 1.8 T1 relaxation curve showing recovery from Mz = 0 following a 90o pulse. 
 
Figure 1.8 shows the T1 relaxation curve. There is no longitudinal magnetization 
following the 90o RF pulse. Longitudinal magnetization is generated as protons release 
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their energy to the lattice. This regeneration of the longitudinal magnetization follows an 
exponential growth process characterized by the T1 time constant.  
Transverse relaxation describes the loss of phase coherence of the magnetization in the 
transverse plane and is characterized by the T2 time constant (Figure 1.9). One 
mechanism that leads to the decay of transverse magnetization is when protons exchange 
energy amongst themselves (spin-spin interactions) resulting random phase following 
energy transfer. This process is also known as spin-spin relaxation. 
The transverse component of magnetization can be written as: 
𝑀𝑥𝑦(𝑡) =  𝑀0 (𝑒−𝑡𝑇2 ) [1.3] 
 
 
Figure 1.9 T2 signal decay in the transverse plane following excitation.  The Blue 
line represents a long T2 decay while the orange line represents a short T2 decay. 
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Figure 1.9 shows the T2 decay curve. Following a 90o RF pulse, the magnetic moments 
of protons have a transverse orientation and rotate together (in-phase) around the 
magnetic field axis. After a short period of time due to spin-spin interactions, the 
directions of the protons begin to spread (dephase) causing the transverse magnetization 
to decay. 
During relaxation of the longitudinal magnetization, individual tissues have different 
levels of magnetization due to their inherently unique T1 values. Similarly, during decay 
of the transverse magnetization, individual tissues have different levels of magnetization 
due to of their unique T2 values. These T1 and T2 relaxation time constants are intrinsic 
features of the underlying tissue and vary according to tissue type. 
MR images are made up of thousands of tiny squares known as pixels (picture element) 
or voxels (volume elements). The signal intensity in the pixel or voxel represents the MR 
signal arising from a volume of tissue that is excited. The greater the MR signal from that 
tissue, the higher will be the signal intensity of that voxel. Various tissues have different 
signal intensities on MR image. The differences of the signal intensity are described as 
image contrast and it allows us to see the boundaries between the tissues. T1 and T2 
values of the tissue are important factors that determine the image contrast. MR imaging 
allows us to produce a wide range of contrasts by changing the acquisition parameters of 
the MRI pulse sequence. 
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The MRI pulse sequence represents a precisely timed series of RF and gradient pulses. 
Gradient pulses create linear variations in the static magnetic field strength and are used 
to produce a spatially localized signal. Figure 1.10 shows one cycle of a hypothetical 
MRI pulse sequence. The repetition time (TR) is defined as the time from the center of 
the first RF pulse to the center of the first RF pulse in the next repetition of the sequence. 
The time at which the signal is measured is the echo time (TE). TE is defined as the time 
between the center of the first RF pulse and the center of the echo.  
 
 
Figure 1.10 A simplified spin echo sequence (phase and frequency encoding gradients 
not shown here). 
 
By varying the TR and TE, image contrast can be manipulated. Varying the TR modifies 
the amount of T1 weighting while varying the TE modifies the amount of T2 weighting 
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in an image. The ability to modify image contrast gives MRI tremendous flexibility. The 
most common pulse sequences used to create contrast in MR imaging are “spin echo”, 
“gradient echo”, and “inversion recovery” sequences.  
 
Spin echo: A basic spin echo pulse sequence consists of two RF pulses (Figure 1.10). The 
first RF pulse is a 90o pulse that excites the protons and produces a FID, and the second 
RF pulse is an 180o pulse that refocuses the transverse magnetization so that the 
dephasing effects resulting from B0 inhomogeneities can be removed. This 180° pulse is 
exactly halfway between the excitation pulse and the echo. It is also known as a 
refocusing pulse since it flips the protons around an axis in the transverse plane. The 
phase that the spins accumulated during the first half of the TE interval is then reversed 
during the second half of the TE interval and the spin echo is formed. 
Gradient echo: A basic gradient echo sequence (GRE) uses a single RF pulse with a flip 
angle (α) of less than 90o. The echo is generated by gradient reversal (Figure 1.11). GRE 
are a class of imaging sequences that do not use an 180o RF pulse to refocus the 
transverse magnetization. The absence of the 180o refocusing pulse allows for faster 
imaging, but makes it sensitive to the effects of B0 inhomogeneities.   
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Figure 1.11 Gradient echo sequence. 
T1-weighted and T2-weighted images can be produced with either spin echo or gradient 
echo sequences. T1w images rely on relatively short values of TR to produce T1-
weighting and very short TE values to eliminate T2-weighting. T2w images rely on very 
long values of TR to eliminate T1-weighting and long TE values to produce T2-
weighting by creating differences in transverse magnetization between tissue types. 
Inversion recovery: Inversion recovery is a variant of a spin echo or gradient echo 
sequence. The only difference is an additional 180o inversion pulse that is applied before 
the excitation pulse. Following the inversion pulse and before the excitation pulse there is 
a delay (known as the inversion time). This inversion time provides a mechanism to use 
differences in T1 relaxation to generate contrast between tissues of interest. One of the 
most common variants of the inversion recovery sequence is the fluid attenuated 
inversion recovery (FLAIR). In a FLAIR sequence, the inversion time is chosen to 
correspond to the zero-crossing point (Figure 1.12) in the T1 relaxation curve of fluid, 
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specifically cerebrospinal fluid (CSF). With signal from CSF nulled, lesions in the brain 
parenchyma appear brighter.  
 
 
Figure 1.12 Inversion recovery sequence. 
 
In routine brain tumor imaging, morphological MR images are usually acquired as pre- 
and post-contrast T1w images, T2w images, and FLAIR images. Contrast agents are 
pharmaceuticals which are used to improve diagnostic information by changing the signal 
intensity differences. They change the intrinsic tissue properties by changing the local 
magnetic field and consequently the T1 and T2 relaxation times. Along with CT, MRI is 
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the first line of diagnostic imaging performed for patients with symptoms suggesting 
brain tumor. T1w images best depict the anatomy of the brain, and, when used with a 
contrast agent they also may show brain pathology. However, T2-weighted images 
provide the best depiction of the tumor, because most tissues that are involved in a 
pathologic process have higher water content than the normal brain matter, and the fluid 
causes the affected areas to appear bright on T2w images. 
Most brain tumors have prolonged T1 and T2 relaxation times and will appear 
hypointense relative to normal brain tissue on a T1w image and hyperintense on a T2w 
image. However, the presence of hemorrhage, necrosis, or calcification can cause a 
heterogeneous appearance of the tumor. On a post-contrast T1-weighted image, the 
contrast (gadolinium) accumulates in the extracellular space of the tumor due to local 
disruption of the blood-brain barrier. As a result, the tumor appears brighter than the 
normal brain tissue on a post-contrast T1-weighted image due to shortening of the T1 
relaxation time constant. 
Morphological MRI is helpful in diagnosis of brain tumors, however morphologic MRI 
alone is insufficient for grading malignant brain tumors, differentiating between tumor 
types, or differentiating between tumor recurrence and radiation necrosis75. Additional 
imaging techniques have been developed to overcome this problem. Tumors can be 
further characterized by using advanced MRI techniques such as diffusion tensor 
imaging, dynamic contrast-enhanced MRI, perfusion MRI and MR spectroscopy76-79. 
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1.3.3 Diffusion Tensor Imaging  
Diffusion Tensor Imaging (DTI) is an advanced MRI technique that provides information 
about the diffusivity of water molecules in the tissue and that can be used to map fiber 
tracts in the brain80, 81, 82. DTI is non-invasive. It utilizes existing MRI technology and 
does not require the administration of a contrast agent. This technique exploits the 
sensitivity of MRI to random water diffusion in the brain tissue in the presence of 
diffusion gradient pulses that are incorporated into the MR imaging pulse sequence.  
To understand diffusion it is important to understand the concept of ‘phase’. Consider 
three sine waves (Figure 1.13) that are oscillating at the same rate but two of them are 
shifted along the x-axis. It can be said that the sine waves have the same frequency but 
different phase. Phase describes the instantaneous position of the sine wave within the 
cyclic variation. Similarly, phase in MRI refers to an angle and describes the position of 
the protons relative to each other. Immediately after the first 900 RF pulse, all the protons 
precess synchronously, they have a phase difference of 0o and are said to be in-phase 
(phase coherence). Due to T2 relaxation and susceptibility differences within tissue 
leading to magnetic field inhomogeneities, the phase coherence disappears and the 
protons are said to be out of phase (dephased). Figure 1.13 (a) shows the protons with 
same phase and (b) different phase. 
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Figure 1.13 Sine waves and protons with (a) same phase and (b) different phase. 
 
In DTI imaging, the 90° RF pulse generates a transverse magnetization that is purposely 
dephased by the application of a large diffusion gradient. If no diffusion is present, the 
protons do not move, and a second diffusion gradient is designed to rephase the 
magnetization completely. However, if diffusion occurs, the protons change their spatial 
position, and the second gradient does not perfectly rephase the magnetization. Since the 
gradients are controlled by the MRI pulse sequence, information about the diffusion 
process can be inferred by measuring the signal with (M) and without (M0) diffusion 
gradients. Figure 1.14 below shows a basic spin echo MRI pulse sequence with the 
addition of diffusion gradients. 
 
(a) (b) 
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Figure 1.14 DTI sequence: spin echo sequence with the addition of diffusion 
gradients. 
 
Diffusion in the anisotropic white matter is modeled as a second-order tensor (Figure 
1.15). To quantify the second-order tensor, measurements are made in at least six non-
collinear directions.  
The diffusion tensor is calculated for each pixel according to the following equation83, 84. 
 
𝑀
𝑀0
= exp(−∑ ∑ 𝑏𝑖𝑗6𝑗=16𝑖=1  𝐷𝑖𝑗)  [1.4] 
𝐷𝑖𝑗 are elements of the diffusion tensor matrix 
 𝑏𝑖𝑗 are elements of the b matrix and is calculated as 𝑏𝑖𝑗 =  𝛾2𝜕2𝐺𝑖𝐺𝑗(∆ − 𝜕3) 
where i, j = x, y, z 
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The tensor can be diagonalized to obtain its eigenvalues (λ1, λ2, λ3). The corresponding 
directions of these eigenvalues are the eigenvectors (e1, e2, e3). The eigenvectors 
represent the tensors principle coordinate, and the eigenvalues describes the shape and 
size of the tensor. Figure 1.15 below shows the diffusion tensor with the eigenvalues. 
  
 
Figure 1.15 Diffusion tensor with eigen values λ1, λ2, λ3. The diffusion is highly 
anisotropic in fibrous tissues such as white matter, and the direction of largest 
diffusivity is generally assumed to be parallel to the local direction of the white 
matter. 
The eigen value information from the diffusion tensor measurements are used to calculate 
the following diffusion tensor parameters: mean diffusivity (MD), fractional anisotropy 
(FA), axial diffusivity (AxD) and radial diffusivity (RD) as shown in the following 
equations:  
Mean Diffusivity (MD): The mean diffusivity is the average of the eigenvalues. 
 𝑀𝐷 = ?̅? = (𝜆1 +  𝜆2 +  𝜆3)/3  [1.5]                              
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Fractional Anisotropy (FA): The fractional anisotropy is the ratio of the anisotropic 
component of the diffusion tensor to the whole diffusion tensor 
𝐹𝐴 =  �3
2
 � (𝜆1−𝜆)���2+(𝜆2−𝜆)���2+ (𝜆3−𝜆)���2 
𝜆12+ 𝜆22+ 𝜆32         [1.6] 
Axial Diffusivity (AxD): The axial diffusivity is the principal eigenvalue. 
𝐴𝑥𝐷 =  𝜆1                [1.7]          
Radial Diffusivity (RD): The radial diffusivity is the average of the radial eigenvalues.  
𝑅𝐷 =  (𝜆2+ 𝜆3)
2
 [1.8] 
 
Table 1.3 Summary of the diffusion tensor parameters. 
Diffusion Tensor 
Parameters 
Formula Description 
Mean Diffusivity  𝜆1 +  𝜆2 +  𝜆33  Average of the eigen values. 
Fractional 
Anisotropy  �32 � (𝜆1 − 𝜆)���2 + (𝜆2 − 𝜆)���2 + (𝜆3 − 𝜆)���2 𝜆12 + 𝜆22 + 𝜆32  Ratio of the anisotropic component of the 
diffusion tensor to the 
whole diffusion tensor. 
Axial Diffusivity 𝜆1 Principal eigen value. 
 
Radial Diffusivity  (𝜆2 +  𝜆3)2  Average of the middle and shorter eigen values. 
 
 
Diffusion is considered isotropic when the eigenvalues are nearly equal. Conversely, the 
diffusion tensor is anisotropic when the eigenvalues are significantly different in 
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magnitude. The magnitudes of eigenvalues are affected by changes in local tissue 
microstructure that occurs due to normal physiological changes (i.e. aging) and also by 
different types of tissue injury or neurological diseases85, 86, 87.  Therefore, the parameters 
derived from the diffusion tensor may be a sensitive probe for characterizing both normal 
and abnormal tissue microstructure.  
There has been strong interest in exploring the clinical applications of DTI in the 
assessment of brain tumors88-92.  DTI has been used for tumor grading93 and tumor 
delineation94. Functional diffusion maps have been used for early assessment of tumor 
response to treatment95. DTI has also been used to differentiate between glioblastoma and 
metastasis96. DTI studies have shown differences in DT parameters in GBM compared to 
MET97. In some studies higher DT parameter values of FA, linear tensor (CL) and planar 
tensor (CP) and lower values of spherical tensor (CS) were observed in GBM and were 
useful for discriminating between the tumor types98-100. 
1.4 Texture Analysis 
Texture is an important characteristic of images and refers to the appearance of the 
image. Image texture is a function of the spatial variation of pixel intensities in an 
image101, 102. Image texture analysis can provide quantitative information in the form of 
texture features that is not visible to human vision103. Texture features are mathematical 
parameters computed from the distribution of pixels, which characterize the texture type 
in the image. The most common method of computing the image texture is to use a 
statistical based method that analyzes the properties of individual pixel intensities and 
their spatial distribution within the image104.  
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Statistical based texture analyses are commonly classified as first-order and second-
order textures, based on the number of pixels defining the local features. First-order 
textures estimate properties of individual pixel values, ignoring the spatial interaction 
between the neighboring image pixels, whereas second-order textures estimate properties 
of two or more pixel values occurring at specific locations relative to each other. 
1.4.1 First-Order Textures 
Textures based on first order statistics are features that can be computed from the gray 
level histogram. The histogram of an image is the count of the number of pixels in the 
image that possess a given grey-level value. Figure 1.16 shows an example gray-level 
histogram. The most common first-order texture features are the mean, standard 
deviation, skewness and kurtosis. 
 
 
Figure 1.16 Gray-level histogram. 
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(1) Mean of the histogram is the mean of the gray-levels in an image.  
?̅? =  1
𝑛
 ∑ 𝑥𝑖𝑛𝑖=1  [1.9] 
  x = gray levels 
  n = number of gray-levels 
(2) Standard deviation is a measure of how far from the mean the gray values in the 
image are distributed.  
𝑠 = �1
𝑛
 ∑ (𝑥𝑖 −  ?̅?)2𝑛𝑖=1   [1.10] 
(3) Skewness of the histogram refers to the asymmetry of the distribution of the gray 
values 105. A distribution is symmetric if the right side of the distribution is similar to the 
left side of the distribution. If the distribution is symmetric, then the skewness value is 
zero. A distribution with an asymmetric tail extending out to the right is referred to as 
positively skewed, while a distribution with an asymmetric tail extending out to the left is 
referred to as negatively skewed.  
The skewness of a distribution is defined as: 
𝑠𝑘 =  1𝑛∑ (𝑥𝑖−?̅?)3𝑛𝑖=1
��
1
𝑛
∑ (𝑥𝑖−?̅?)2𝑛𝑖=1  �3  [1.11] 
(4) Kurtosis is a measure of how flat or peaked the top of a symmetric distribution is 
when compared to a normal distribution. If the grey level distribution is similar to the 
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normal distribution, the kurtosis value is 3. Flat-topped distributions are referred to as 
platykurtic and have a kurtosis value of less than 3, while less flat-topped distributions 
are referred to as leptokurtic and have a kurtosis value greater than 3.  
The kurtosis of a distribution is defined as: 
𝑘 =  1𝑛∑ (𝑥𝑖−?̅?)4𝑛𝑖=1
��
1
𝑛
∑ (𝑥𝑖−?̅?)2𝑛𝑖=1  �4  [1.12]   
The limitation of the histogram-based measurements is that they carry no information 
regarding the relative spatial position of pixels with one another. The spatial relationship 
of the pixels can be incorporated by taking in to account the distribution of intensities as 
well as the position of pixels with equal or nearly equal intensity values. This can be 
achieved by constructing a gray level co-occurrence matrix as explained in the next 
section. 
1.4.2 Second-Order Textures 
Textures based on second-order statistics are features that can be computed from the gray 
level co-occurrence matrix (GLCM). The GLCM is a two-dimensional histogram of gray-
levels for a pair of pixels separated by a fixed distance (d) at a fixed angle (θ)103. 104.  It is 
an estimate of the joint probability G(i, j) of the intensity values of two pixels (i and j), at 
a certain pixel distance apart along a given direction (i.e., the probability that i and j have 
the same intensity). This joint probability takes the form of a square matrix with row and 
column dimensions equal to the number of discrete gray levels (intensities) in the image. 
If an intensity image contained no texture (intensity variations) the resulting GLCM 
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would be completely diagonal. As the image texture increases (i.e. as the local pixel 
intensity variations increase), the off-diagonal values in the GLCM become larger. 
GLCMs are usually computed with neighboring pixels defined in angular directions 0o, 
45o, 90o and 135o. 
Figure 1.17 shows an example to construct a GLCM. Consider a 4x4 image (Figure 
1.17a) with 4 gray-levels from 0 to 3 (Figure 1.17b). A generalized GLCM is shown in 
Figure 1.17c where (i, j) stands for the number of times gray-level i and j satisfy the 
condition stated by the offset distance vector d and angle θ. 
The resulting four GLCMs for d = [0 1] and [0 -1] and θ = 0o, 45o, 90o, 135o are shown in 
Figure 1.17d-g. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 a Sample image. .17a Sample image. Figure 1.17b Gray-levels in the 
sample image. 
 
 36 
 
 
(i, j) 0 1 2 3 
0 (0,0) (0, 1) (0, 2) (0, 3) 
1 (1,0) (1, 1) (1, 2) (1, 3) 
2 (2,0) (2, 1) (2, 2) (2, 3) 
3 (3,0) (3, 1) (3, 2) (3, 3) 
 
 
4 2 1 0 
2 4 0 0 
1 0 6 1 
0 0 1 2 
  
 
 
6 0 2 0 
0 4 2 0 
2 2 2 2 
0 0 2 0 
          
 
GLCMs as seen above are symmetric matrices. Hence either upper or lower triangle is 
used for calculation of the second-order features. Each element in the GLCM is the 
4 1 0 0 
1 2 2 0 
0 2 4 1 
0 0 1 0 
 2 1 3 0 
1 2 1 0 
3 1 0 2 
0 0 2 0 
Figure 1.17c: general form of a GLCM  
 
Figure 1.17d: GLCM for θ = 0o           Figure 1.17e: GLCM for θ = 45o       
 
 
Figure 1.17d: GLCM for θ = 90o           Figure 1.17e: GLCM for θ = 135o           
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probability of co-occurrence of the pixel gray-levels. The second-order texture features 
can then be calculated using the formulas shown below. 
Each of the five GLCM-based second-order texture features that are used in this thesis 
are described below:  
(1) Entropy is the measure of randomness of the GLCM. It describes the amount of chaos 
or disorder within the elements of the GLCM. Entropy is higher when the image is non-
uniform. 
𝐸𝑛𝑡𝑟𝑜𝑝𝑦 =  −∑ 𝐺(𝑖, 𝑗)𝑖,𝑗 𝑙𝑜𝑔2𝐺(𝑖, 𝑗) [1.13] 
 G(i, j) = probability of co- occurrence of the pixel gray-levels 
(2) Homogeneity measures the closeness of the distribution of elements in the GLCM to 
the GLCM diagonal. It is also known as inverse difference moment. It is sensitive to the 
near diagonal elements of the GLCM. It is higher for a diagonal GLCM.  
𝐻𝑜𝑚𝑜𝑔𝑒𝑛𝑒𝑖𝑡𝑦 =  ∑ 1
1+|𝑖−𝑗|𝐺(𝑖, 𝑗)𝑖,𝑗  [1.14] 
(3) Inertia measures the intensity or gray-level variation between the reference pixel and 
its neighbor over the whole image. It describes the local variations in the GLCM. It is 
inversely correlated to homogeneity and will be lower for a diagonal GLCM. 
𝐼𝑛𝑒𝑟𝑡𝑖𝑎 =  ∑ (𝑖 − 𝑗)2𝑖,𝑗 𝐺(𝑖, 𝑗) [1.15]  
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(4) Correlation measures how correlated a reference pixel is to its neighbor over the 
whole image. It describes the joint probability occurrence of the specified pixel pairs. 
Correlation is 1 or -1 for a perfectly positively or negatively correlated image. 
𝐶𝑜𝑟𝑟𝑒𝑙𝑎𝑡𝑖𝑜𝑛 =  ∑ (𝑖−𝜇)(𝑗−𝜇)𝐺(𝑖,𝑗)
𝜎2𝑖,𝑗  [1.16] 
𝜇 𝑎𝑛𝑑 𝜎  𝑎𝑟𝑒 𝑡ℎ𝑒 𝑚𝑒𝑎𝑛 𝑎𝑛𝑑 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛. 
(5) Energy describes the uniformity of the image. It measures the sum of squared 
elements of the GLCM. It is also known as angular second moment feature. Energy is 
high if the image is homogenous. 
𝐸𝑛𝑒𝑟𝑔𝑦 =  ∑ 𝐺(𝑖, 𝑗)2𝑖,𝑗  [1.17] 
 
1.4.3 Texture Analysis of Medical Images 
MR images hold a large amount of texture information that may be relevant for clinical 
diagnosis. Due to its inherent resolution limitation, MR images are not capable of 
providing microscopic tissue information that can be evaluated visually. However, 
histological changes present in various diseases may generate textural changes in the MR 
image that can be quantified through texture analysis.  
Image texture analysis has been used in a range of MR studies for classifying tissues in 
brain tumors.  It has also been used to differentiate between different tumor grades106 and 
discriminate between benign, malignant, and normal tissue types on MR images107. 
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Texture analysis has been used to study the effects of traumatic brain injury on texture 
features108. Genetic features have been discovered by texture analysis that could favor 
prognosis in low grade oligodendroglioma109. Texture analysis has been used to segment 
structures in the normal brain110, 111 as well as in epilepsy to identify abnormalities in the 
hippocampus112 by detecting differences in the texture features.  
Image texture analysis has been used in a range of CT and MRI studies for classifying 
non- cerebral tissues. Texture analysis has been used on computed tomography (CT) 
images to detect microcalcification in breast cancer113, microcalcification susceptibility 
effects on breast MRI114, and to analyze breast tumors on contrast-enhanced MRI 115. 
Texture differences were observed in MR images of the spinal cord between normal 
subjects and patients with relapsing multiple sclerosis before the atrophy was visually 
detectable116.Texture analysis has also been successfully applied to the classification of 
pathological tissues in the lungs117 and skeletal muscles118. 
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1.5 Thesis Objectives 
1.5.1 Objective 1: Multiparametric imaging in patients with 
glioblastoma 
Glioblastoma multiforme (GBM) is the most aggressive form of primary brain tumor. 
The current standard of care for patients with GBM is surgery followed by chemo- and 
radiation therapy. Since GBM is a grade IV tumor, recurrences are common even after 
the treatment. Radiation injury (RI), a side effect of radiation therapy and tumor 
recurrences appears hyperintense on conventional MR images. Differentiating between 
RI and tumor recurrences is important for treatment planning. Numerous techniques have 
been utilized trying to find biomarkers for differentiation, however biopsy is still the gold 
standard. The purpose of our current study was to determine whether a multiparametric 
characterization of tissue based on correlations of T2w signal intensity, FLAIR signal 
intensity, and diffusion tensor imaging parameters could differentiate RI from tumor 
recurrence.  
1.5.2 Objective 2: Texture analysis in differentiating between 
glioblastoma and metastasis  
Glioblastoma and metastasis are the two most common types of brain tumor. Both types 
of tumors exhibit similar radiologic appearance on routine MR images. Differentiating 
between GBM and MET is very important because they have different biological 
mechanisms and require different treatment strategies. Previous studies have focused on 
advanced imaging modalities, such as diffusion tensor imaging, perfusion MRI, MR 
spectroscopy and perfusion CT, that require longer scan times and expertise in advanced 
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imaging, which results in increased cost, examination time, and exposure to radiation. 
The goal of our current study was to use texture based image analysis on routine MR 
images to provide quantitative information that can be used to differentiate between 
GBM and MET. 
1.5.3 Objective 3: Texture analysis in patient selection for radiation 
therapy 
Whole brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS) is frequently used 
to treat metastatic brain tumors. However, SRS has side effects related to necrosis and 
edema, and requires separate and relatively invasive localization procedures. Helical 
tomotherapy (HT) allows for a SRS-type simultaneous infield boost (SIB) of multiple 
brain metastases, synchronously with WBRT and without separate stereotactic 
procedures. However, some patients’ tumors may not respond to HT type WBRT+SIB, 
and would be more appropriately treated with radiosurgery or conventional surgery 
despite the additional risks and side effects. The goal of the current study was to 
investigate whether quantitative measurements of tumor size and appearance (including 
first- and second-order texture features) on a magnetic resonance imaging (MRI) scan 
acquired prior to treatment could be used to differentiate responder and non-responder 
lesions after HT type WBRT+SIB treatment of metastatic disease of the brain.  
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2 Analysis of morphological MRI parameters and diffusion 
tensor parameters for perfusion CT derived high 
permeability areas in glioblastoma: identifying tumor 
recurrence from radiation induced necrosis 
2.1 Introduction 
Glioblastoma multiforme (GBM) is the most lethal and aggressive form of primary brain 
tumor. Median survival for patients with glioblastoma is 12-15 months1. Treatment 
options are determined by tumor size, location, and associated symptoms. Advances in 
brain tumor treatment have led to aggressive management strategies utilizing 
combinations of surgery, chemotherapy, and radiation therapy. The current standard of 
care for patients with GBM is surgical resection of the tumor followed by radiation 
therapy and concomitant and adjuvant temozolomide chemotherapy. This approach has 
been shown to standardize the treatment protocol and prolong the overall survival for 
patients2.  Radiation Injury (RI) is an undesirable but unavoidable side effect of treatment 
that appears as enhancing lesions following contrast agent injection on magnetic 
resonance imaging (MRI). Since GBM is a high grade tumor, recurrences are common 
after treatment, and these recurrences also manifest as hyperintense regions on MRI after 
contrast agent injection. Therefore the presence of enhancing lesions after radiation 
therapy may represent either tumor recurrence or radiation induced injury3, 4. Similarly, 
both recurrent tumor and radiation are also known to produce hyperintense regions on 
T2-weighted (T2w) and fluid attenuated inversion recovery (FLAIR) MRI.  Although 
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important for treatment planning and prognosis, differentiating between tumor 
recurrence and RI can be difficult with conventional MRI5. 
Currently tumor biopsy or histology is the gold standard for differentiating tumor from 
RI. There have been various attempts to differentiate tumor recurrences from RI in the 
past using in-vivo morphologic imaging as well as various functional imaging techniques 
such as CT perfusion, MR perfusion, diffusion weighted imaging, magnetic resonance 
spectroscopy (MRS), single-photon emission computed tomography, and positron 
emission tomography5, 6-18.  However, each modality has its limitations and therefore the 
search for an accurate and easy to implement technique continues19.   
Numerous studies have successfully correlated CT perfusion properties of the tumor with 
histology and shown that progressive or recurrent tumors have high permeability (PS) 
compared to RI regions20-22. CT has been widely used to obtain perfusion information in 
brain tumor, but it has several disadvantages that include additional cost, examination 
time, and increased exposure to radiation. Since MRI is part of routine brain tumor 
imaging, an MRI technique that provides similar information would be advantageous.  
The purpose of the current study was to determine whether a multiparametric 
characterization of tissue based on T2w signal intensity, FLAIR signal intensity, and 
diffusion tensor imaging parameters could differentiate RI from tumor recurrence.  
Tumor recurrence was defined as tissue with high permeability and high blood volume 
measured by CT perfusion. RI was defined as tissue with low permeability measured by 
CT perfusion that was hyperintense on FLAIR MRI23-24.  We hypothesized that 
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correlations between MRI parameters could identify regions of high vascular 
permeability and therefore could differentiate RI from tumor recurrence. 
2.2 Methods 
This study was approved by the University of Western Ontario Health Sciences Research 
Ethics Board. All patients provided written informed consent prior to imaging. Twelve 
patients with glioblastoma multiforme were recruited for the study. Patients were eligible 
for this study if they met the following criteria: histologically proven cancer before 
radiation and chemotherapy, magnetic resonance imaging findings on follow-up clinical 
MRI and clinical presentation consistent with glioblastoma. Patients underwent a 
perfusion CT scan and a 3 Tesla MRI. Of the twelve patients, two did not complete the 
perfusion CT scan and two patients showed no increase in permeability values and 
therefore could not be used in the analysis. Higher permeability values were 
approximately ten times the normal values. Table 2.1 shows the patient demographics 
and tumor location. 
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Table 2.1 Patient demographics and clinical information. 
Patient  Gender, Age Brain tumor location 
1 M, 44 Lt. Parietal 
2 M, 46 Lt. Parietal, Corpus Callosum 
3 M, 57 Lt. Parieto-Occipital 
4 M, 50 Lt. Temporal 
5 F, 64 Rt. Parietal 
6 M, 56 Lt. Temporal  
7 F, 63 Rt. Temporal-Occipital 
8 M, 43 Rt. Frontal 
 
MR imaging was performed on a 3T Tim Trio MRI system (Siemens Medical Systems, 
Erlangen, Germany) with a 32-channel head coil. The MR imaging protocol included the 
following sequences: transverse T2-weighted (T2w) fast spin-echo (repetition time= 6000 
ms, echo time = 93 ms, field of view = 220 mm, slice thickness = 2 mm; matrix = 320 × 
320), transverse FLAIR (repetition time = 9000 ms, inversion time = 2500 ms, echo time 
= 91 ms, field of view = 256 mm, slice thickness = 5 mm; matrix = 256 x 256), and 
 61 
 
 
diffusion-weighted spin-echo imaging (repetition time = 7500 ms, echo time = 90 ms, 
number of directions = 64, field of view = 256 mm, b-value = 1000, slice thickness = 2 
mm; matrix = 128x128). 
2.2.1 CT Perfusion Imaging 
The patients were scanned on a GE CT scanner (GE LightSpeed VCT; GE Healthcare, 
Waukesha, WI) with a nonionic contrast bolus (Iomeron, 350 mg iodine/mL, 40 mL; 
Bracco Imaging Scandinavia, Goteborg, Sweden). A two-phase CT perfusion scan, 
guided by a prior non-contrast CT scan that identified eight 5 mm sections to cover the 
tumor, was performed for each patient. The bolus of contrast was injected into the vein at 
a rate of 2 to 4 mL/s at 3 to 5 seconds after the first phase started. The preselected brain 
sections were scanned for 45 seconds at 1-second intervals during the first phase and for 
a period of 105 seconds at 15-second intervals during the second phase. All patients were 
scanned at 80 kVp with a 250 mm field of view. 
2.2.2 Data Analysis 
The CT perfusion studies were analyzed using the prototype version of CT Perfusion 4D 
software (GE Healthcare, Waukesha, WI), which is based on the Johnson-Wilson model25 
and is insensitive to the delay between arterial and tissue time-attenuation curve (TAC) to 
generate a map of permeability. For each patient, the arterial and venous regions of 
interest (ROIs) were automatically chosen by the software in one of the anterior cerebral 
arteries and the posterior superior sagittal sinus, respectively. The venous TAC was used 
as a reference to correct for the partial volume averaging of the arterial TAC25. Tissue 
TACs were measured from 2 x 2 pixel blocks of the CT images. Parametric perfusion 
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maps of permeability (PS) were calculated by deconvolving the arterial TAC with each 
tissue TAC using the Johnson-Wilson model25.  
The diffusion tensor imaging (DTI) data were analyzed using Brainvoyager QX software 
(Brain Innovation, Maastricht, The Netherlands). From the DTI dataset six independent 
elements of the diffusion tensor were determined for each voxel, and the eigen values 
(λ1, λ2, λ3) of the diffusion tensor were calculated. The eigen value information was used 
to calculate the following diffusion tensor parameters26: mean diffusivity (MD), 
fractional anisotropy (FA), axial diffusivity (AxD) and radial diffusivity (RD) as shown 
in the following equations (1-4):  
𝑀𝐷 =  𝜆1 +  𝜆2 +  𝜆3   [2.1] 
𝐹𝐴 =  �3
2
 � (𝜆1−𝜆)���2+(𝜆2−𝜆)���2+ (𝜆3−𝜆)���2 
𝜆12+ 𝜆22+ 𝜆32   [2.2] 
𝐴𝑥𝐷 =  𝜆1  [2.3]         
𝑅𝐷 =  (𝜆2+ 𝜆3)
2
 [2.4] 
The diffusion tensor maps of MD, FA, AxD, RD, the T2w images, the FLAIR images, 
and the permeability maps were all coregistered in 3D slicer27.  
Three regions of interest (ROIs) were selected for each patient. The ROIs were selected 
using the PS map and the coregistered FLAIR images simultaneously. ROI1 was defined 
within a high permeability region on the PS map and a high signal intensity region on 
FLAIR. ROI1 was labeled as a high permeability region attributed to tumor. ROI2 was 
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defined as a high signal intensity region on FLAIR with normal permeability on the PS 
map and attributed to radiation induced necrosis (RI).  A region on the white matter on 
the contralateral side with normal signal intensity on FLAIR and normal permeability on 
the PS map was selected as ROI3, and labeled as normal tissue. For each patient, the 
three ROIs were used to extract the mean MD, FA, AxD, and RD values from the 
diffusion tensor maps and the mean T2-weighted and FLAIR signal intensities. The 
values in ROI1 (high permeability) and ROI2 (RI) were normalized by the values in the 
normal tissue on the contralateral side. These normalized values were used for statistical 
comparisons. 
All statistical comparisons were performed with SPSS software version 21 (SPSS, IBM, 
Chicago, IL). Independent sample t-tests were conducted to determine if there were 
differences in the normalized DTI parameters, the T2w signal intensity (SI) and FLAIR 
signal intensity between the high permeability region and RI region.  A Pearson product-
moment correlation was computed to determine whether there was an association 
between the measured MRI parameters in both the high permeability (tumor) and low 
permeability (RI) regions. 
2.3 Results 
A typical FLAIR image (Figure 2.1A), T2W image (Figure 2.1B), CT perfusion map 
(Figure 2.1C), and blood flow map (Figure 2.11D) from a single subject were used to 
visualize the tumor and tissue with RI. The FLAIR image with the corresponding 
permeability map overlaid is shown in Figure 2.1E.  Based on these images, regions of 
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interest in the high permeability area (green), the high intensity area (brown), and the 
normal area (yellow) on the contralateral side were defined (Figure 2.1F).   
 
 
Figure 2.1a-f  FLAIR, T2w images, PS and CBV maps, and the ROIs used for 
analysis. 
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Table 2.2 provides the mean and standard deviation (SD) of each measured parameter in 
the high permeability (tumor) and low permeability (RI) regions and the p-values.  There 
were no significant differences in the T2w (p =.94) and FLAIR (p = .99) signal intensities 
between the high permeability region and the RI region. Also there were no significant 
differences in the diffusion tensor parameters FA (p = .82), MD (p = .44), AxD (p = .33) 
and RD (p = .56) comparing the high permeability region to the RI region. 
Table 2.2 Parameters measured in the high permeability and RI regions. 
Normalized 
Parameters  
High Permeability Region 
(mean ± SD) 
RI Region 
(mean ± SD) 
p-value 
  
FA .73 ± .29 .77 ± .35 .82 
MD 1.14 ± .47 .97 ± .36 .44 
AxD 1.04 ± .42 .87 ± .24 .33 
RD 1.23 ± .54 1.07 ± .50 .56 
T2w SI .96 ± .33 .94 ± .42 .94 
FLAIR SI .94 ± .43 .94 ± .36 .99 
 
As expected, there was a strong positive correlation between MD and RD (r = .98, p < 
.01) in both the high permeability (tumor) region and in the low permeability (RI) region 
(r = .98, p < .01).  The low permeability (RI) region also produced a strong negative 
correlation between FA and RD (r = - .76, p < .05) and a strong positive correlation 
between T2w signal intensity and FLAIR signal intensity (r = .89, p < .01). These 
associations are summarized in Figure 2.2. 
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Figure 2.2a-f  Scatterplots summarizing the correlation analysis. 
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2.4 Discussion    
Differentiating radiation injury (RI) from recurrent or progressive tumor in patients with 
glioblastoma is essential since the prognoses and treatment for the two entities is 
different. Conventional morphologic imaging alone has failed to differentiate tumor 
regions from RI regions. With the advent of newer aggressive treatment options, RI is on 
the rise and the follow-up imaging of patients over time is becoming more complex. 
Diffusion MRI has shown promise in differentiating these two entities to a limited 
extent5, 13. Various other imaging techniques also offer moderate success due to the 
complexity of the tissue microenvironment and the inherent limitations of these 
modalities and techniques.   
The goal of this study was to determine whether morphological MRI and diffusion tensor 
imaging (DTI) could differentiate tumor recurrence from RI. The morphological 
parameters we explored were T2w SI and FLAIR SI, while the diffusion tensor 
parameters we explored were FA, MD, AxD, and RD.  We did not find any statistically 
significant differences in the means of the measured parameters in the high permeability 
(tumor) region and the low permeability (RI) region. 
There was a significant correlation between MD and RD in both the high permeability 
region and RI region. Such a correlation is expected because infiltrating tumor cells can 
cause an increase in MD and RD while edema from radiation damage can also cause a 
similar increase31. Therefore the correlation between MD and RD may not be a good 
marker to distinguish the two regions. Interestingly, a significant negative correlation was 
observed between FA and RD and a significant positive correlation was observed 
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between T2w SI and FLAIR SI in the low permeability (RI) region. A decrease in FA 
can be caused by vasogenic edema due to radiation injury13, 29, which can in turn cause an 
increase in RD (the radial component of diffusion)30. Therefore the presence of vasogenic 
edema could explain why FA has a significant negative correlation with RD in the RI 
region. These correlations were not observed in the high permeability (tumor) region. 
Therefore, the correlations between FA and RD, and between T2w SI and FLAIR SI may 
differentiate these two regions.  
Further work is needed to determine whether these correlations could help differentiate 
high permeability regions from radiation injury.  One possible approach would involve 
identifying suspicious regions and then correlating DTI parameter values and 
mophological MRI values on a pixel-by-pixel basis from within the ROI. If a significant 
correlation was found, it may indicate radiation injury.  This success of this approach 
depends on the heterogeneity of the tissue within the ROI. 
To date, no objective study on correlation analyses of diffusion tensor parameters has 
shown any diagnostic potential in patients with glioblastoma multiforme. Our study had 
several limitations. First, the patient population was small, and further investigation with 
a larger patient population is necessary to confirm these preliminary findings. Further 
large-scale studies would provide estimates of the accuracy and diagnostic utility of this 
new method. The second limitation of this study is the use of permeability maps to select 
possible tumor regions. There have been numerous studies that have successfully 
correlated perfusion properties of tumors with histology, and shown that progressive or 
recurred tumors have high permeability compared to RI regions20-22. Ideally in a future 
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study the tumor regions would be confirmed histologically, which is the current gold 
standard. 
Perfusion CT is widely used for differentiating RI from tumor tissue but has several 
disadvantages that include additional cost, examination time, increased exposure to 
radiation, and increased post-processing and reading time. Obtaining similar information 
directly from MRI would circumvent these disadvantages. T2, FLAIR and DTI are part 
of routine clinical MRI protocols for brain tumor patients. The results of the present study 
suggest that correlations observed among routine MRI parameters may help differentiate 
RI from tumor. 
In conclusion, our results indicate that the significant correlations of diffusion tensor 
imaging parameters FA and RD, along with the significant correlations of morphological 
MRI parameters of T2w SI and FLAIR SI, could be used to differentiate recurred tumor 
from RI regions in patients with GBM. 
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3 Differentiating between glioblastoma and metastasis 
using first- and second-order MR image texture 
3.1 Introduction 
Glioblastoma multiforme (GBM) and metastasis (MET) are the two most common types 
of brain tumors in adults1. These tumors can have similar appearance on magnetic 
resonance imaging (MRI) specifically a necrotic mass surrounded by ring-like 
enhancement and extensive edema2-4.  Discriminating between these two types of tumor 
remains challenging when the patient presents with a solitary enhancing mass, since both 
types of tumors exhibit similar radiologic appearance4. Differentiating between GBM and 
MET is very important because they have different biological mechanisms and require 
different treatment strategies5, 6. Histopathologic analysis of a biopsy sample from the 
tumor region is the only currently accepted method to make a definitive diagnosis7, 8. The 
use of noninvasive methods is preferable and sometimes mandatory when a biopsy is not 
possible because of the general condition of the patient or if the mass is located near a 
critical area. Therefore, it would be clinically beneficial to have a noninvasive method of 
differentiating between these tumor types without the need for biopsy9. Since routine 
MRI is not very useful for non-invasively differentiating between these two types of 
tumor, many studies have focused on advanced imaging modalities, such as diffusion 
tensor imaging10-13, perfusion MRI14,15, MR spectroscopy16-19 and perfusion  CT20-23. The 
advanced imaging modalities that have been used require longer scan times, expertise in 
advanced imaging, and additional imaging modality like CT which increases cost, 
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examination time, and patient exposure to radiation. Since MRI is part of the routine 
brain tumor imaging, a technique based on routine MRI that would provide quantitative 
information without the additional cost would be highly advantageous. 
Image texture analysis has been used in a range of studies for classifying tissues24-26 in 
breast and brain tumors. Image texture is a function of the spatial variation of pixel 
intensities in an image27.  Texture analysis can provide quantitative information that is 
not visible to human vision28. The most common technique to compute image texture is 
to use statistical based methods, namely first- and second-order textures, which analyze 
properties of individual pixel intensities and their spatial distribution within the image.  
The purpose of the current study was to determine whether first- and second- order image 
texture properties of GBM and MET could be used to differentiate between these two 
types of tumor. We hypothesized that the texture properties of GBM and MET tumor 
tissue on post-contrast T1-weighted (T1w) MRI are different, and therefore these texture 
properties could be used to differentiate GBM from MET. This study compares four first-
order texture features: the mean signal intensity, standard deviation of the signal 
intensity, skewness, and kurtosis; and five second-order texture features: entropy, 
homogeneity, inertia, correlation, and energy of GBM and MET tumors. 
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3.2  Methods 
Thirty-Nine (39) patients with a diagnosis of brain metastasis and 31 patients with a 
diagnosis of glioblastoma multiforme were evaluated retrospectively for this study. All 
patients had undergone routine brain MR examination before radiation treatment and/or 
surgical resection at London Health Sciences Center, Canada. The tumors that were 
resected fulfilled the 2007 WHO histopathologic criteria for diagnosis1.  
MR imaging was performed on a 1.5T GE Signa MRI system (GE Healthcare, 
Milwaukee, Wisconsin). The MR imaging protocol included pre- and post-contrast T1w 
sequences. Post-contrast images were acquired immediately after contrast injection. A 3D 
spoiled gradient echo sequence was used to acquire the T1w images with the following 
parameters: repetition time: 8.84 msec, echo time: 3.47 msec, slice thickness: 2 mm, 
matrix size: 512 × 512, flip angle: 13º.  
3D lesion contouring on the post-contrast T1w MR images was performed under the 
supervision of a radiation oncologist with expertise in the treatment of brain tumors using 
ITK-SNAP (Version 2.4.0)29. The contours were saved as 3D label maps. Figure 3.1 
shows the post-contrast T1w images of GBM and MET lesions, with the contours 
overlaid on the images. 
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Figure 3.1 Post-contrast T1w image of GBM and MET lesion, with the contour 
overlaid. 
Type of tumor Post-contrast T1w 
image  
Contour overlaid 
GBM  
 
 
 
 
 
MET  
 
 
 
 
 
 
3.2.1 Data Analysis 
All calculations were performed using Matlab 7.1. (The Mathworks Inc., Natick, MA, 
USA).  For each lesion, we calculated the following first- and second-order texture 
features: (1) mean T1w signal intensity, (2) standard deviation of the T1w signal 
intensity, (3) skewness, (4) kurtosis, (5) information entropy of the T1w signal intensity 
histogram, (6) homogeneity, (7) inertia, (8) energy, and (9) correlation. Features (1) 
through (4) are first-order texture measures that are estimated from individual pixel 
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values in the tumor region. Features (5) through (9) are second-order texture features 
that were calculated based on a gray-level co-occurrence matrix (GLCM)30, 31, 32.  
The GLCM approach is based on the use of second-order statistics of the grayscale image 
histograms and is an estimate of the second-order joint probability G(i, j) of the intensity 
values of two pixels (i and j), at a certain pixel distance apart along a given direction (i.e., 
the probability that i and j have the same intensity). This joint probability takes the form 
of a square matrix with row and column dimensions equal to the number of discrete gray 
levels (intensities) in the image. If an intensity image contained no texture the resulting 
GLCM would be completely diagonal. As the image texture increases (i.e. as the local 
pixel intensity variations increase), the off-diagonal values in the GLCM become larger.  
The images were quantized to thirty-two gray levels, and four 32 × 32 GLCMs were 
computed with neighboring pixels defined in angular directions of 0, 45, 90 and 135. The 
resulting texture features were averaged over the four directions. Each GLCM-based 
second-order texture feature was calculated as follows:  
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Table 3.1 GLCM-based second-order texture features  
Feature Equation Description 
Entropy −�𝐺(𝑖, 𝑗)
𝑖,𝑗 𝑙𝑜𝑔2𝐺(𝑖, 𝑗) Measures the randomness of the GLCM. 
Homogeneity 
�
11 + |𝑖 − 𝑗|𝐺(𝑖, 𝑗)
𝑖,𝑗  Measures the closeness of the distribution of elements in the GLCM to the GLCM diagonal. 
Inertia �(𝑖 − 𝑗)2
𝑖,𝑗 𝐺(𝑖, 𝑗) Measures the intensity contrast between a pixel and its neighbor over the whole image. Describes the local variations in the 
GLCM. 
Correlation 
�
(𝑖 − 𝜇)(𝑗 − 𝜇)𝐺(𝑖, 𝑗)
𝜎2
𝑖,𝑗  
Measures how correlated a pixel is to its 
neighbor over the whole image. Describes 
the joint probability occurrence of the 
specified pixel pairs. 
Energy � 𝐺(𝑖, 𝑗)2
𝑖,𝑗  Measures sum of the squared elements of the GLCM. It describes the uniformity of 
the image. 
 
3.2.2 Statistical Analysis 
All statistical analysis was performed using SPSS software (IBM SPSS, Version 21, 
Chicago, IL).  Kolmogorov-Smirnov test was used to assess the normality of the data. 
Mann-Whitney U test was conducted to test the differences between the two groups 
(GBM and MET). P < .05 was considered to indicate a statistically significant difference.   
The efficacy of the texture features for classification was evaluated using logistic 
regression analysis. The first- and second-order texture features were combined into a 
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multivariate logistic regression analysis to determine the most significant parameters 
and to build an optimal logistic regression model (LRM) to classify GBM and MET. 
Model fit was evaluated by means of the Hosmer–Lemeshow goodness-of fit test33. 
Areas under the receiver operating characteristic (ROC) curves were computed for each 
of the first- and second-order texture features. ROC curves were also computed for the 
predictive features that were the calculated from the LRM. ROC curve analyses were 
performed to determine optimum threshold and the diagnostic accuracy of each 
histogram parameter for discriminating the two types of tumors. These analyses allowed 
us to determine the sensitivity, specificity, 95 % confidence interval (CI), standard error 
(SE), and area under the curve (AUC) associated with each individual texture parameter 
and combined texture parameter as a function of the threshold value used to discriminate 
the two types of tumors. 
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3.3 Results 
The independent samples Mann-Whitney U test for the first-order texture features 
showed significant differences in the standard deviation of the T1w signal intensity for 
the GBM and MET groups. No differences were found in T1w signal intensity, skewness 
and kurtosis between the GBM and MET groups. Table 3.2 shows the mean and standard 
deviation (SD) of each first-order texture feature for the GBM and MET, as well as the 
result of the Mann-Whitney U test for each feature. Figure 3.2 summarizes the results in 
form of bar graphs for each of the first-order texture feature. 
 
Table 3.2 Mean and SD of each of the first-order texture feature. 
First-Order Texture 
Feature 
GBM 
(mean ± SD) 
MET 
(mean ± SD) 
p-value 
 
T1w Signal Intensity 1382 ± 660.62 1194 ± 808.27 .08 
SD T1w Signal Intensity 438 ± 258.21 312 ± 235.29 .02 
Skewness .159 ± .39 .079 ± .50 .52 
Kurtosis 2.85 ± .74 2.97 ± .63 .22 
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The independent samples Mann-Whitney U test for the second-order texture features 
showed significant differences in the entropy, homogeneity, inertia and energy feature for 
the GBM and MET groups. No differences were found in the correlation feature for the 
GBM and MET groups. Table 3.3 shows the mean and standard deviation of each 
second-order texture feature for the GBM and MET, as well as the result of the Mann-
Whitney U test for each feature. Figure 3.3 summarizes the results in form of bar graphs 
for each of the second-order texture feature. 
 
Table 3.3 Mean and SD of each of the second-order texture feature. 
Second-Order Texture 
Feature 
GBM 
(mean ± SD) 
MET 
(mean ± SD) 
p-value 
  
Entropy 10.18 ± 1.11 9.32 ± 1.46 .007 
Homogeneity .995 ± .003 .998 ± .001 .000 
Inertia .320 ± .183 .155 ± .092 .000 
Correlation .915 ± .047 .914 ± .065 .615 
Energy .981 ± .013 .992 ± .005 .000 
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Figure 3.2 Plots of the first-order texture features for GBM and MET. Standard 
deviation of the T1w signal intensity was the only significantly different feature 
between the two tumor types. 
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Figure 3.3 Plots of the second-order texture features for GBM and MET. Contrast, 
homogeneity, energy and entropy features were significantly different between the 
tumor types. 
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3.3.1 ROC curve analysis: 
Each texture feature was evaluated for its discriminative ability using ROC analysis as 
shown in Table 3.4 and Figure 3.4, 3.5 and 3.6. When used alone, second-order texture 
feature of inertia (AUC= .790) was the best feature for discrimination, followed by 
homogeneity (AUC= .776), energy (AUC= .752) and entropy (AUC= .688). The first-
order texture features of mean of the T1w signal intensity (AUC= .621), standard 
deviation of the T1w signal intensity (AUC= .659), skewness (AUC= .544) and kurtosis 
(AUC= .585) were not very useful in discriminating the tumor types.  
The LRM of the combined first- and second-order texture features was the most accurate 
in differentiating the tumor types with AUC= 0.885, sensitivity = 90.3%, specificity = 
82.1 % and cutoff value = 0.673. The LRM of the second-order texture features also 
showed good accuracy differentiating the tumor types with AUC= 0.840, sensitivity = 
83.9 %, specificity = 66.7 % and cutoff value = 0.708 compared to the individual second-
order textures. The LRM of the first-order texture features was a poor discriminator of 
the tumor types with AUC= 0.658, sensitivity = 61.3%, specificity = 64.1 % and cutoff 
value = 0.562. The optimum threshold, sensitivity, and specificity of each texture 
parameter and combined texture parameters to distinguish the two tumor types are 
summarized in Table 3.4 
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Table 3.4 ROC curve analysis for each of the first- and second-order texture 
features and combination of the first- and second-order texture features for 
differentiation between GBM and MET. (the cut-off value was chosen as a point on 
the ROC curve that maximizes sensitivity + specificity) 
Texture Feature Cut-off Value  Sensitivity Specificity AUC SE CI 
Mean T1w 
1073 61.3 56.4 .621 .067 (.49, .75) 
Std T1w 
305 67.7 64.1 .659 .065 (.53, .78) 
Skewness 
.054 58.1 48.7 .544 .069 (.40, .68) 
Kurtosis 
2.91 64.5 56.4 .585 .070 (.44, .72) 
Entropy 
9.74 71.0 64.1 .688 .064 (.56, .81) 
Homogeneity 
.998 74.2 71.8 .776 .062 (.65, .89) 
Inertia 
.180 71.0 71.8 .790 .054 (.68,.89) 
Correlation 
.929 64.5 53.8 .535 .072 (.39, .67) 
Energy 
.992 74.2 66.7 .752 .063 (.62, .87) 
First order 
.562 61.3 64.1 .658 .067 (.52, .79) 
Second order 
.708 83.9 66.7 .840 .047 (.74, .93) 
First + Second 
order .673 90.3 82.1 .885 .043 (.80, .97) 
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Figure 3.4 ROC curves for each of the first-order texture measures: mean T1w 
signal intensity (AUC= .621), standard deviation (std) of the T1w signal intensity 
(AUC= .659), skewness (AUC= .544) and kurtosis (AUC= .585). All four features 
have poor predictive value. 
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Figure 3.5 ROC curves for the second-order texture measures: entropy (AUC = 
.688), inertia (AUC= .790), homogeneity (AUC= .776), correlation (AUC= .535), and 
energy (AUC= .752). Inertia, homogeneity and energy (next page) are the best 
predictors for differentiating between GBM and MET when used alone. 
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Figure 3.5 (contd): ROC curve for the second-order texture measure of energy. 
 
Figure 3.6 ROC curves for the first order textures (AUC = .658), second-order 
textures (AUC = .840) and combined first + second-order texture measures (AUC = 
.885). Combining the first and second order textures may provide the best predictive 
accuracy for differentiating between GBM and MET. 
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3.4 Discussion 
GBM and MET typically demonstrate similar appearances on routine MR imaging. Since 
they have same clinical symptoms but different treatment strategies, a technique is 
needed to differentiate between these two types of tumors.  In this study we investigated 
the feasibility of using texture-based analysis of routine MR images to differentiate GBM 
from MET. Texture analysis provides quantitative information about the spatial variation 
of pixel intensities in an image. 
We investigated four first-order texture features (mean T1w signal intensity, standard 
deviation of the T1w signal intensity, skewness, and kurtosis) and five second-order 
texture features (entropy, homogeneity, inertia, correlation, and energy). First-order 
texture features are computed from gray level histogram while second order texture 
features are computed from the gray level co-occurrence matrix (GLCM) which analyzes 
gray level distribution of pairs of pixels. Figure 3.8a and 3.8b show sample GBM and 
MET images having similar radiologic appearance, where the second-order texture 
features of inertia, energy, and homogeneity are able to successfully differentiate between 
GBM and MET. 
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 a GBM MET 
Image 
  
Inertia 7.475 5.594 
Energy 0.0050 0.0133 
Homogeneity 0.4468 0.5336 
 
b GBM MET 
Image 
  
Inertia 9.248 3.114 
Energy 0.0136 0.0186 
Homogeneity 0.4987 0.6063 
Figure 3.4a,b GBM and MET tumors showing similar appearance on routine MR 
image but differences in the second-order texture measures. 
 
A statistically significant difference was observed in the standard deviation of the mean 
T1w signal intensity. The first-order texture features of mean, skewness, and kurtosis did 
not show any significant differences between the two types of tumors. A statistically 
significant difference was observed in the second-order texture features of entropy, 
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inertia, homogeneity, and energy. No statistically significant difference was seen in the 
second-order texture feature of correlation.  
ROC analysis showed that the combination of first- and second-order texture features had 
the largest AUC (0.88) and would have the best predictive accuracy for differential 
diagnosis between GBM and MET, followed by the combined second-order texture 
features (AUC= 0.84). The individual second-order texture features of inertia (AUC= 
.79), homogeneity (AUC= .77), and energy (AUC= .75) also showed good predictive 
accuracy. The combined first-order texture features (AUC= .65) was not very useful in 
differentiating the tumor types. 
Other investigators have used advanced imaging techniques including diffusion and 
perfusion to differentiate between the two types of tumor10-15. Previous studies have also 
used a region of interest (ROI) approach within the whole tumor to derive imaging 
parameters for differentiation. However, this may not be the suitable approach since a 
small ROI in a large tumor may not provide information about the changes occurring 
within the tumor and may not be a good indicator of the global change within the entire 
tumor. Our technique is unique in several ways: (1) This is the first study to apply first- 
and second-order texture analysis for differentiating between GBM and MET tumors, (2) 
we use the routine clinical MR images instead of advanced imaging modalities to 
discriminate between the two tumor types, which saves time and cost; (3) we use a 
whole-tumor approach rather than small ROIs drawn inside the tumors. Our approach 
yields information about the textural properties of the whole tumor rather than a small 
ROI within the tumor: and (4) the simplicity of implementation makes it desirable than 
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other techniques. Simple mathematical calculations are used to compute the texture 
parameters. 
A limitation of this study is the small sample size. Features that may have less effect on 
the differentiation may have been missed. Features which were approaching significance, 
such as the mean of the T1w signal intensity (p =.08), may become statistically 
significant with a larger sample size. Even within our sample size we had significant 
effects that were useful, suggesting that the texture features we found to be significant are 
important in differentiating GBM from MET. Another limitation is that the performance 
of the LRM is unclear without the use of a separate validation set, and further evaluation 
of the models need to be explored in future work on a larger data set.  
3.5 Conclusions 
We have demonstrated the ability of texture-based analysis of routine MR images to 
differentiate between GBM and MET. Our results indicate that the combination of first- 
and second-order texture features provides us with the highest predictive accuracy 
followed by the combined second-order features. When used individually, the second 
order texture feature of inertia had the best predictive accuracy followed by homogeneity 
and energy. Given the simplicity of our technique and availability of the post-contrast 
T1w MR images which are part of the routine brain tumor imaging, we believe this 
method may have practical significance and may become a useful tool for differentiating 
between GBM and MET.  
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4 MRI-based prediction of response to whole-brain helical 
tomotherapy with simultaneous intralesional boost for 
metastatic brain cancer using quantitative size and 
appearance features 
4.1 Introduction 
Metastatic brain tumors are an important public health issue, with 20%–40% of patients 
having solid tumors subsequently developing symptomatic brain metastases1, and 
approximately 150,000 annual brain metastasis diagnoses annually in the United States. 
With recent improvements in diagnostic imaging and increasing patient survival due to 
improved systemic cancer control, the incidence of intracranial metastatic disease is 
projected to rise2. Whole brain radiotherapy (WBRT) is widely used in the treatment of 
patients with metastatic disease and involves the delivery of a uniform dose of radiation 
to the entire brain3. It improves symptoms, but longer-term survivors may develop 
neurocognitive deficits4, 5. Stereotactic radiosurgery (SRS) is a more targeted form of 
radiation therapy in which a higher dose of radiation is delivered to the tumor in a single 
treatment session. SRS combined with WBRT has been shown to yield superior local 
control, as compared with WBRT alone6. However, SRS has a higher frequency of side 
effects related to brain tissue necrosis and edema, which can put pressure on surrounding 
healthy brain tissue. SRS also requires separate localization and treatment procedures that 
add cost and patient inconvenience. Depending on the SRS system used, invasive 
immobilization devices may be needed, increasing patient discomfort. In addition, the 
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sequential delivery of WBRT and SRS does not allow integration of radiation delivery 
across both components, limiting the ability to fully optimize the radiation dose. 
Helical tomotherapy (HT) and volumetric modulated arc therapy (VMAT) are two 
radiotherapy delivery technologies that allow for radiosurgery-type simultaneous infield 
boost (SIB) treatments to be given synchronously with the standard WBRT dose, and in 
this way be used to efficiently boost multiple brain metastases without the need for 
separate stereotactic procedures7,8. The ability to incorporate this boost contribution with 
larger field volumes as part of the treatment planning optimization process provides an 
advantage of this WBRT+SIB strategy over sequential WBRT and SRS. During 
fractionated radiotherapy, reassortment and reoxygenation may occur between 
treatments, resulting in increased efficacy of subsequent doses in the treatment course; 
single-fraction treatments cannot exploit these radiobiologic properties9. Although 
WBRT+SIB has potential advantages compared to surgery and SRS, it is not necessarily 
appropriate for every patient. Some patients’ tumors may not respond to WBRT+SIB, 
and would be more appropriately treated with radiosurgery or conventional surgery 
despite the additional risks and side effects. A means for predicting response to 
WBRT+SIB based on pre-treatment imaging could support the selection of the best 
treatment for each individual lesion as early as possible while the metastatic lesion has 
the greatest chance of control. 
As a first step toward a broader objective of developing a means for response prediction 
to WBRT+SIB, the goal of this study was to determine whether quantitative 
measurements of tumor size and appearance on a magnetic resonance imaging (MRI) 
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scan acquired prior to treatment could be used to differentiate responder and non-
responder lesion groups after WBRT+SIB using HT (henceforth WBHT+SIB) treatment 
of metastatic disease of the brain.  In this study, we used the longest axial diameter (as 
used in Response Assessment Criteria in Solid Tumors [RECIST] measurements10 and 
the 3D volume as the measure of tumor size.  To measure imaging appearance, we used 
three first-order features (the mean signal intensity, standard deviation of the signal 
intensity, and skewness of the intensity histogram) and five second order texture features 
(entropy, homogeneity, inertia, correlation and energy). 
4.2 Materials and methods 
4.2.1 Materials 
This study was approved by the Human Subjects Research Ethics Board of our institution 
and informed consent was obtained from all patients.  We recruited 21 patients for the 
study. These 21 patients had a total of 31 lesions. Inclusion criteria were: histologic 
diagnosis of primary cancer; contrast-enhanced MRI demonstrating 1–3 metastases 
within 6 weeks of study enrollment; age ≥ 18 years; Karnofsky performance status ≥ 70; 
anticipated survival ≥ 3 months; extracranial disease controlled; to be treated, or  absent. 
Exclusion criteria were: metastases not suitable for SIB (> 3 lesions or any lesion 
maximum diameter > 3 cm, metastases within 5 mm of brainstem or optic apparatus, 
evidence of leptomeningeal spread, intracranial extension of an osseous metastasis, 
evidence of intraventricular or subependymal growth), prior cranial radiotherapy, 
concurrent cytotoxic chemotherapy, contraindications to MRI or gadolinium contrast. 
The patients underwent HT with 30 Gy WBRT and 60 Gy SIB in 10 fractions at the 
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London Regional Cancer Program, London Health Science Centres, Canada. Figure 4.1 
illustrates the isodose curves for a 60 Gy/10-fraction WBHT+SIB case.  
 
Figure 4.1 Isodose curves for an HT plan, illustrating a whole brain radiation plan 
(yellow = 30Gy) with integrated high-dose boost (purple = 60Gy) to a metastatic 
lesion. 
 
For each patient, we acquired pre-treatment and post-treatment T1-weighted (T1W) 
gadolinium contrast-enhanced MRI scans (for an overall total of 21 × 2 = 42 scans) using 
3D spoiled gradient echo sequence (repetition time: 8.84 msec, echo time: 3.47 msec, 
slice thickness: 2 mm, matrix size: 512 × 512, flip angle: 13º). The mean time between 
the baseline and follow-up scans was 3.4 months (range 1–6 months). Imaging was 
performed on a 1.5 Tesla General Electric Signa HDxt MRI scanner (GE Healthcare, 
Waukesha, WI, USA).  
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 Patient 1 Patient 2 Patient 3 
Pre-
treatment 
Image 
   
Post-
treatment 
image 
   
Figure 4.2 Sample images of brain metastases at the pre-treatment and follow-up 
imaging time points, with manual contours overlaid in red.  Note the variability of 
MRI appearance of the different lesions. 
 
Table 4.1 Primary site of metastasis for non-responders and responders  
Primary Site 
Number of Non-
responding lesions 
Number of 
Responding lesions 
Breast 4 1 
Melanoma 3 3 
Lung 1 8 
Colon 1 0 
Kidney 4 0 
Parotid 1 0 
Thyroid 1 0 
Prostate 0 3 
Unknown 1 0 
 
 104 
 
 
 
 
Figure 4.3 Representative axial cross sections from inferior (left) to superior (right) 
of two tumors, one in each row.  The tumor in the first row (a) had a standard 
deviation of 375.79 within its core region.  The tumor in the second row (b) had a 
standard deviation of 238.97 within its core region.  The higher standard deviation 
value in the upper tumor is reflective of the more variegated texture within the 
tumor; bright pixels are sometimes neighbouring bright pixels, but are also 
sometimes neighbouring dark pixels; the correlation between intensities of 
neighbouring pixels is not as high as in the tumor in the second row. 
 
 
 
 
 
 105 
 
 
4.2.2 Methods 
3D lesion contouring on the post-contrast T1W MR images was performed by a radiation 
oncologist with expertise in treatment of brain metastases using ITK-SNAP (Version 
2.4.0) for all the baseline and follow-up lesions11. The regions enclosed by the contours 
were recorded as 3D binary label maps.  All subsequent image processing and data 
analysis was performed using Matlab 7.1 (The Mathworks Inc., Natick, MA, USA). 
The longest diameter lying entirely within tumor tissue on any axial slice for each lesion 
was calculated based on the 3D binary label maps according to the Response Evaluation 
Criteria in Solid Tumors (RECIST) 1.1 guidelines10. For each lesion, the percentage 
change in RECIST was calculated as 100% × (follow-up RECIST - baseline RECIST) / 
baseline RECIST. Lesions with a percentage change in RECIST of ≤ -30% were grouped 
as responders (15 lesions), with the remainder of the patients grouped as non-responders 
(16 lesions), according to the RECIST guidelines for clinical assessment10.  
Measures of size and appearance were computed on each 3D contoured tumor, as well as 
on two tumor subregions, defined as follows. The 3D binary label maps were 
automatically separated by software into two regions: a peripheral region intended to 
correspond to the tumor rim, and the remaining region intended to correspond to the 
tumor core.  The rim was defined as the set of image voxels within 3 mm of the tumor 
boundary on each slice within each 3D tumor.  The core was defined as the set of image 
voxels on the inside of the tumor and not within the rim. 
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Inspired by qualitative categorizations of metastases as “homogeneous”, 
“heterogeneous”, and “rim-enhancing” in related work in the SRS context12,13, we 
calculated the following features for each tumor and its subregions: (1) 3D tumor volume 
(number of voxels within the contoured tumor × voxel size), (2) tumor diameter, (3) 
mean T1W signal intensity, (4) standard deviation of the T1W signal intensity, (5) 
skewness, (6) information entropy of the T1W signal intensity histogram, (7) 
homogeneity, (8) inertia, (9) energy, (10) correlation, and (11) the ratio of mean intensity 
within the rim to mean intensity within the core (henceforth rim:core ratio). Features (1) 
and (2) are size measures. Features (3)–(5) are first-order appearance and texture 
measures. Features (6)–(10) are a subset of the Conners and Harlow second-order texture 
features14 and were calculated based on a gray-level co-occurrence matrix (GLCM) 𝑔, 
where 𝑔(𝑖, 𝑗) contains the number of neighbouring pixels having intensities 𝑖 and 𝑗. Each 
GLCM-based feature was calculated as follows:  
homogeneity = ∑ 1
1+|𝑖−𝑗|𝑔(𝑖, 𝑗)𝑖,𝑗 ,  
inertia = ∑ (𝑖 − 𝑗)2𝑖,𝑗 𝑔(𝑖, 𝑗),  
energy = ∑ 𝑔(𝑖, 𝑗)2𝑖,𝑗 , and  
correlation = ∑ (𝑖−𝜇)(𝑗−𝜇)𝑔(𝑖,𝑗)
𝜎2𝑖,𝑗 .  
Images were quantized to 60 gray levels and we computed four GLCMs with neighboring 
pixels defined in angular directions of 0, 45, 90 and 135. For each axial slice containing 
tumor, a single GLCM was constructed from the sum of the four GLCMs taken in each 
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direction.  These slice-wise GLCMs were then summed to produce a final GLCM, from 
which the texture features were calculated. 
Kolmogorov-Smirnov tests were used to assess the normality of the distributions of the 
data. Mann-Whitney U tests were conducted to test for significant differences between 
the medians of the two groups (responders and non-responders), with α = 0.05. Receiver 
operating characteristic (ROC) curve analyses were performed for each feature 
independently and areas under the curves (AUC) were computed. ROC curve analysis 
was conducted using the SPSS software package (IBM SPSS, Version 21, Chicago, IL). 
4.3 Results 
Table 4.2 shows the median and interquartile range (IQR) of each feature within each 
group for the whole tumor, as well as the result of the Mann-Whitney U test for each 
feature. Tables 4.3 and 4.4 show the same information for the core and rim regions, 
respectively, although for these regions only the appearance measures, not the size 
measures, were calculated as the sizes of the rim and core are directly correlated with the 
size of the whole tumor.  For the whole tumor and for the core region, significant 
differences in median tumor diameter, 3D volume, and second-order homogeneity, 
inertia, correlation, and energy were found.  For the rim region, significant differences in 
homogeneity, inertia and energy were found. For the whole tumor, the 3D volume 
measure had a smaller p-value, compared to the tumor diameter measure.  For all 
significant differences, non-responders had larger 3D volume, diameter, inertia, and 
correlation values, and smaller homogeneity and energy values.  Figures 4.4, 4.5 and 4.6 
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shows box and whisker plots for features found to be significant, to graphically illustrate 
the differences between the groups.   
 
Table 4.5 shows the AUC values for the three top-performing individual features, as well 
as the optimal thresholds (chosen as the upper left-most points on the ROC curves).  In 
addition, logistic regression was done to examine combined performance of the variables, 
and we calculated the AUC yielded by the combination of the best-performing size 
measure (tumor 3D volume) and the best-performing appearance measure (core 
correlation) to investigate whether the combination of size and appearance characteristics 
would yield improved per-patient prediction of response.  This combination did not 
outperform the measure of core correlation. The threshold shown in Table 4.5 for this 
feature combination is on the response variable from the logistic regression model. 
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Table 4.2 Feature values measured for each group in the whole tumor.  For rows 
with p < 0.05, the larger median is underlined. 
 
Feature 
  
Responders 
(median ± IQR) 
Non-responders 
(median ± IQR) 
p-value 
  
3D volume (mm3) 1326 ± 2529 3879 0.01  ± 7120 
Tumor diameter 17.8 ± 12.1 24.1 0.03  ± 15.0 
T1W signal intensity 1369 ± 1723.7 1199 ± 885.1 0.24 
SD T1W signal intensity 466.1 ± 441.6 339.7 ± 271.6 0.39 
Skewness 0.04 ± 0.56 0.11 ± 0.72 0.67 
Entropy 9.7 ± 2.0 10.1 ± 1.3 0.67 
Homogeneity 0.998 0.997 ± 0.002  ± 0.001 0.02 
Inertia 0.25 ± 0.20 0.35 0.02  ± 0.22 
Correlation 0.93 ± 0.05 0.95 0.03  ± 0.02 
Energy 0.995 0.993 ± 0.007  ± 0.004 0.01 
Rim:core ratio 0.73 ± 0.16 0.66 ± 0.14 0.73 
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Table 4.3 Feature values measured for each group in the tumor core.  For rows with 
p < 0.05, the larger median is underlined. 
 
Feature 
  
Responders 
(median ± IQR) 
Non-responders 
(median ± IQR) 
p-value 
  
T1W signal intensity 1382.9 ± 2005.2 1240.6 ± 900.7 0.22 
SD T1W signal intensity 390.7 ± 366.8 334.6 ± 290.9 0.48 
Skewness 0.09 ± 0.41 0.15 ± 0.86 0.95 
Entropy 9.62 ± 2.1 9.90 ± 1.6 0.46 
Homogeneity 0.9987 ± 0.001 0.9981 ± 0.001 0.02 
Inertia 0.34 ± 0.28 0.44 0.04  ± 0.20 
Correlation 0.90 ± 0.07 0.93 <0.01  ± 0.02 
Energy 0.996 0.994 ± 0.007  ± 0.004 0.01 
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Table 4.4 Feature values measured for each group in the tumor rim.  For rows with 
p < 0.05, the larger median is underlined. 
  
Feature 
  
Responders 
(median ± IQR) 
Non-responders 
(median ± IQR) 
p-value 
  
T1W signal intensity 1082.3 ± 1100.9 830.3 ± 510.8 0.19 
SD T1W signal intensity 359.2 ± 304.4 230.9 ± 235.9 0.41 
Skewness 0.69 ± 0.47 0.83 ± 0.65 0.29 
Entropy 9.44 ± 1.41 9.73 ± 1.5 0.82 
Homogeneity 0.9986 ± 0.0008 0.9984 ± 0.0008 0.03 
Inertia 0.56 ± 0.27 0.74 ± 0.29 0.03 
Correlation 0.79 ± 0.02 0.79 ± 0.02 0.70 
Energy 0.996 ± 0.002 0.995 ± 0.002 0.03 
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Figure 4.4 Boxplots for 3D volume and Diameter for the whole tumor, the core, and 
rim regions, comparing responders (R) and non-responders (NR). 
 
 
Figure 4.5 Boxplots for Homogeneity and Inertia for the whole tumor, the core, and 
rim regions, comparing responders (R) and non-responders (NR). 
 
 
 113 
 
 
 
Figure 4.6 Boxplots for Correlation and energy for the whole tumor, the core, and 
rim regions, comparing responders (R) and non-responders (NR). 
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Figure 4.7 ROC curves for the four features that had the largest AUCs (Table 4.4). 
 
 
Table 4.5 Optimal thresholds of features having the four largest AUCs. 
 
Features AUC  Threshold 
Tumor 3D Volume .75 2154  
Tumor Diameter .72 16.84  
Core Correlation .77 0.92 
Combined (core correlation +3D volume)  .77 0.32 
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4.4 Discussion 
The role of brain radiotherapy has been a source of controversy since some patient 
populations show limited clinical benefit15. WBRT is widely used in the treatment of 
patients with metastatic disease16 since it is technically easy to deliver and it improves 
symptoms in 75% of symptomatic patients with brain metastases17,18, but long-term 
survivors may develop neurocognitive deficits4,5 and local control may be inadequate, 
especially in patients who live longer than a few months.  
The feasibility and safety of HT+SIB using 30 Gy WBRT with intralesional boost of 60 
Gy has been shown by Rodrigues et al. in a phase I clinical trial7. For selected patients 
with brain metastasis, aggressive treatment of the individual lesions with high dose 
radiation combined with a lower dose of radiation to the remainder of the brain has 
produced the best results in terms of controlling cancer in the brain and preventing new 
lesions from developing22. HT allows for radiosurgery-type SIB treatments to be given 
synchronously with the standard WBRT dose, and can be used efficiently to boost 
multiple brain metastases without the need for separate stereotactic procedures7,8. 
Bauman et al. have shown that the WBHT+SIB strategy is also relatively independent of 
the number of lesions being boosted and may be a feasible strategy for treating multiple 
intracranial lesions efficiently19. 
In this study, we investigated size and imaging appearance features of the whole tumor, 
tumor rim and tumor core for differentiation of patient groups that would benefit from the 
WBHT+SIB therapy for brain metastases. This is the first study to apply quantitative size 
and imaging texture measures of tumors to measure the differences on pre-treatment 
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contrast-enhanced T1-weighted MRI between responders and non-responders to helical 
tomotherapy with simultaneous infield boost for intracranial metastases. Our approach 
adapts and extends previous work in the stereotactic radiosurgery context by using 
quantitative measures that are related to previously used categorical subjective tumor 
assessments. To measure imaging appearance, we used three first-order features (the 
mean signal intensity, standard deviation of the signal intensity, and skewness) derived 
from the gray-level histogram, where mean and standard deviation are the mean of the 
gray-levels and the measure of deviation of these gray-levels in the image, while 
skewness is the asymmetry of the distribution of the gray-levels. We also tested five 
second order texture features (entropy, homogeneity, inertia, correlation and energy) 
which are calculated from the GLCM, where GLCM provides an estimate of the joint 
probability of the intensity values of neighboring pixels. The use of these predictive 
markers could help to identify the lesions which would benefit from WBHT+SIB 
(responders) while sparing the non- responders which would not benefit so that the latter 
may be treated with other combinations of therapies. For the former group of lesions, 
WBHT+SIB may represent an effective and less invasive option compared to traditional 
combinations of surgery or radiosurgery combined with WBRT.    
For the whole tumor, size measures of 3D volume and diameter were significantly 
different between the responders and non-responders with responders having smaller size 
tumors than the non-responders. One possible explanation for the limited response of 
large tumors is related to the presence of hypoxic regions. Hypoxic regions are resistant 
to radiation damage23. During the course of fractionated WBHT + SIB treatment, smaller 
hypoxic regions may become reoxygenated and therefore may be more sensitive to 
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radiation damage. Conversely, larger tumors have bigger hypoxic regions that may need 
more fractionated radiation delivery (>15 fractions) than is currently used in clinical 
settings.   
Appearance measure of first-order features did not show any significant differences 
between the groups. Second-order features of homogeneity, inertia, correlation and 
energy showed significant differences between the two groups.  Figure 4.3a-b shows an 
example of the differences in the standard deviation (SD) and correlation values for the 
two patients. The tumor in the first row (4.3a) had a SD value of 375.79 and correlation 
value of 0.89 within its core region.  The tumor in the second row (4.3b) had a SD value 
238.97 and correlation value of 0.97 within its core region. The lower correlation value in 
the upper tumor is reflective of the more variegated texture within the tumor and the 
correlation between intensities of neighbouring pixels is not as high as in the tumor in the 
second row.  
Since the tumor appears to have a hypodense core and a hyperintense rim, we also looked 
at the first and second order texture features separately for each of the two regions (the 
tumor core and tumor rim) to assess whether separating the two regions would give us 
better predictive capability. For the core region, we saw similar results to that of the 
tumor as a whole. Core size measures of 3D volume, tumor diameter and second-order 
appearance measures of homogeneity, inertia, correlation and energy were significantly 
different between the responders and non-responders groups. For the rim region, the size 
measure of 3D volume and second-order features of homogeneity inertia and energy were 
significantly different between the two groups. To investigate the predictive value of an 
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enhancing rim and/or a necrotic core, we calculated the rim-core ratio. No significant 
difference was seen for the rim-core ratio between the responder and non-responder 
groups. The AUC for the ROC curve (0.46) of rim-core ratio feature was very low, 
suggesting that the appearance (or lack thereof) of an enhancing rim or necrotic core on 
the pre-treatment image may not predict response at first follow-up. 
 
For all three regions (tumor, core, rim), no significant differences were seen in the first-
order features of T1w signal intensity and SD between the responders and non-responders 
suggesting that the T1w signal intensity and SD may not be useful as a predictive marker 
for response to WBHT+SIB therapy.  The failure to detect statistical significance for the 
first-order texture features for the three regions may imply that the global appearance of 
the tumor may be less important than the local pixel intensity relationships to prediction 
of WBHT+SIB treatment response. Further testing of this observation will require greater 
statistical power with a larger sample size.  
There are several limitations to this study. First, all the contours were drawn by a single 
observer; further study is required to measure the impact of observer contouring 
variability on the size and appearance measures used in this study. Second, our sample 
size necessitates that the results of this study be considered hypothesis-generating, with 
more extensive validation required on a separate data set. Third, although our study tested 
a subset of the Conners and Harlow second-order texture features14, this does not 
constitute an exhaustive evaluation of the texture measures that have been proposed, so 
firm conclusions regarding the predictive power of appearance measures in general 
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cannot be drawn from the results of this study and further investigation of alternative 
texture measures is required. Fourth, the texture measure of T1w signal intensity was not 
normalized.  Although this parameter was not significantly different between the two 
groups, factors such as coil loading may have increased the variance of the measured 
signal intensity. In the future a quantitative approach should be taken24 to measure the 
absolute T1 of the tissue for texture analysis. Finally, the logistic regression model's 
performance on a separate validation set should be explored in future work on a larger 
data set. 
Metastatic brain lesion size and second order appearance as measured on pre-treatment 
MRI can distinguish responders from non-responders to WBHT+SIB. . The results of this 
study suggest that the 3D tumor volume and the second-order correlation texture measure 
within the tumor core are the best predictors, with smaller lesions (< 2.1 cm3) and those 
with a relatively smaller second order core correlation value (< 0.92) having a greater rate 
of response to WBHT+SIB. The results also suggest that the longest axial diameter (as 
measured in RECIST) could be a useful surrogate for 3D volume, with tumors having 
diameters < 1.7 cm responding more favorably to treatment.  Appearance measures in 
general can quantify visual changes but they did not substantially outperform measures of 
size; there is high variability of appearance in both responders and non-responders to 
WBHT+SIB. The amount of rim enhancement and/or core necrosis, as reflected in our 
signal intensity measures did not provide useful prediction of response. Ongoing work on 
a larger sample size will include further validation of our results and the development of 
an approach to per-lesion prediction of response to WBHT+SIB therapy based on pre-
treatment MRI, supporting optimal treatment selection. 
 120 
 
 
4.5 References 
 
[1] Kondziolka D, Martin JJ, Flickinger JC, Brufsky AM, Baar J, Kirkwood JM, 
Lunsford LD. Long term survivors after gamma knife radiosurgery for brain 
metastases. Cancer 2005; 104(12):2784–91. 
[2] Patel TR, McHugh BJ, Bi WL, Minja FJ, Knisely JP, Chiang VL. A 
comprehensive review of MR imaging changes following radiosurgery to 500 
brain metastases. AJNR Am J Neuroradiology 2011; 32(10):1885-92. 
[3] Sneed PK et al., Neurosurgery Clinics of North America 1996; 7:505–515.  
[4] Eichler AF, Loeffler JS. Multidisciplinary management of brain metastases. 
Oncologist 2007; 12(7):884-98. 
[5] Asai A, Matsutani M, Kohno T, Nakamura O, Tanaka H, Fujimaki T, Funada N, 
Matsuda T, Nagata K, Takakura K.. Subacute brain atrophy after radiation therapy 
for malignant brain tumor. Cancer 1989; 63(10):1962-74. 
[6] Sneed PK, Lamborn KR, Forstner JM, McDermott MW, Chang S, Park E, Gutin 
PH, Phillips TL, Wara WM, Larson DA. Radiosurgery for brain metastases: is 
whole brain radiotherapy necessary? Int J Radiat Oncol Biol Phys. 1999; 
43(3):549-58. 
[7] Rodrigues G, Yartsev S, Yaremko B, Perera F, Dar AR, Hammond A, Lock M, Yu 
E, Ash R, Caudrelier JM, Khuntia D, Bailey L, Bauman G. Phase I trial of 
simultaneous in-field boost with helical tomotherapy for patients with one to three 
brain metastases 201; 80(4):1128-33. 
[8] Lagerwaard F, Van der hoorn EA, Verbakel WF, Haasbeek CJ, Slotman BJ, Senan 
S. Whole brain radiotherapy with simultaneous integrated boost to multiple brain 
metastases using volumetric modulated arc therapy.  Int J Radiat Oncol Biol Phys 
2009; 75(1):253–9. 
 121 
 
[9] Hall EJ, Brenner DJ. The radiobiology of radiosurgery: rationale for different 
treatment regimes for AVMs and malignancies. Int J Radiat Oncol Biol Phys 1993; 
25(2):381–5. 
[10] Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey 
J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shanker L, Dodd L, Kaplan R, 
Lacombe D, Verweij J. New response evaluation criteria in solid tumors: revised 
RECIST guideline (version 1.1). European  Journal of Cancer 2009; 45(2):228–47.  
[11] Yushkevich PA , Piven J , Hazlett HC, Smith RG, Ho S, Gee JC , Gerig G. User-
guided 3D active contour segmentation of anatomical structures: Significantly 
improved efficiency and reliability. Neuroimage 2006; 31:1116-28. 
[12] Goodman KA, Sneed PK, McDermott MW, Shiau CY, Lamborn KR, Chang S, 
Park E, Wara WM, Larson DA. Relationship between pattern of enhancement and 
local control of brain metastases after radiosurgery.  Int J Radiat Oncol Biol Phys 
2001; 50(1), 139–46. 
[13] Rodrigues G, Zindler J, Warner A, Lagerwaard F. Recursive partitioning analysis 
for the prediction of stereotactic radiosurgery brain metastases lesion control. The 
Oncologist 2013; 18(3):330–5. 
[14] Conners RW, Harlow CA. A theoretical comparison of texture algorithm.  IEEE 
Transactions in Pattern Analysis and Machine Learning 1980; 2(3):204–22. 
[15] Nieder C, Mehta MP. Prognostic indices for brain metastases--usefulness and 
challenges. Radiation Oncology 2009; 4:10. 
[16] Sneed PK, Larson DA, Wara WM. Radiotherapy for cerebral metastases. 
Neurosurgical Clinics of North America 1996; 7:505-515. 
[17] Borgelt B, Gelber R, Kramer S, Brady LW, Chang CH, Davis LW, Perez CA, 
Hendrickson FR.. The palliation of brain metastases: Final results of the first two 
 122 
 
studies by the Radiation Therapy Oncology Group. International Journal of 
Radiation Oncology Biology Physics 1980; 6(1): 1-9. 
[18] Markesbery WR, Brooks WH, Gupta GD, Young AB. Treatment for patients with 
cerebral metastases. Archives of Neurology 1978; 35(11):754-756. 
[19] Bauman G, Yartsev S, Fisher B, Kron T, Laperriere N, Heydarian M, VanDyk J. 
Simultaneous infield boost with helical tomotherapy for patients with 1 to 3 brain 
metastases. American Journal of Clinical Oncology 2007; 30(1):38-44. 
[20] Brown JM, Diehn M, Loo B. Stereotactic ablative radiotherapy should be 
combined with a hypoxic cell radiosensitizer. International Journal of  Radiation 
Oncology Biology Physics 2010; 78(2):323–7. 
[21] Levegrün S, Pottgen C, Wittig A, Lubcke W, Jawad JA, Stuschke M. International 
Journal of  Radiation Oncology Biology Physics 2013; 86(4):734–42. 
[22] Kondziolka D, Patel A, Lunsford D, Kassam A, Flickinger J. Sterotactic 
radiosurgery plus  Whole brain radiotherapy versus radiotherapy alone for patients 
with multiple brain metastasis, Int. J. Radiation Oncology Biol. Phys 1999; 
45(2):427–434. 
[23] Wachsberger P, Burd R, Dicker A.Tumor Response to Ionizing Radiation 
Combined with Antiangiogenesis or Vascular Targeting Agents: Exploring 
Mechanisms of Interaction. Clinical Cancer Research 2003;9:1957-1971. 
[24] Deoni SC, Peters TM, and Rutt BK. High-resolution T1 and T2 Mapping of the 
Brain in a Clinically acceptable time with DESPOT1 and DESPOT2, Magnetic 
Resonance in Medicine 2005; 53: 237-241 
 123 
 
5 Conclusion and Future Work 
This thesis addresses important questions about improving the detection of brain tumor 
recurrence following treatment, differentiating glioblastoma from metastasis using 
quantitative texture parameters, and improving patient selection for helical tomotherapy 
type whole brain radiation therapy with simultaneous infield boost. The main scientific 
contributions are summarized below. 
5.1 Multiparametric Imaging in Patients with 
Glioblastoma  
GBMs are the most malignant form of primary brain tumor where recurrences are 
common even after surgery and chemo-radiation therapy1. Discrimination of tumor from 
radiation injured tissue is essential for guiding proper surgical and radiotherapy 
treatments since tumor recurrences and radiation injury (RI) have similar appearance on 
follow-up conventional magnetic resonance imaging2, 3 (MRI). There have been 
numerous attempts to differentiate tumor recurrences from RI using various functional 
imaging modalities such as CT, MRI, single-photon emission computed tomography and 
positron emission tomography, however biopsy is still the gold standard. DTI derived 
parameters have been used in an attempt to differentiate tumor16 from radiation injury. 
The AxD parameter showed significant differences between the tumor region and RI 
region. Other DTI parameters like FA, MD and RD showed no significant differences 
between the two regions16.  The majority of the studies that were performed to 
differentiate tumor recurrence from RI had no histopathological verification4,5 of the final 
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diagnosis and most of these studies were retrospective4,6. A search for an accurate 
technique to differentiate tumor from RI continues. As described in Chapter 2 we did not 
see significant differences in the diffusion tensor parameters between the two groups. 
Instead, we have shown that correlations between diffusion tensor parameters and routine 
MRI signal intensities were significant and may be able to differentiate the tumor regions 
from radiation injured regions. In this study we used perfusion CT information along with 
FLAIR images to separate the tumor regions from radiation injured regions. This was 
based on the numerous studies that have successfully correlated perfusion properties of 
tumors with histology, and have shown that progressive or recurrent tumors have high 
permeability compared to RI regions7,8,9. The correlation of MRI signal intensity values 
from FLAIR and diffusion tensor parameters is a novel approach that was tested on a 
small group of patients. The preliminary results from this study require further 
investigation with a larger patient population to confirm our initial findings and provide 
estimates as to the accuracy and diagnostic utility of this new method. In future studies 
the tumor regions would need to be confirmed histologically, which is the current gold 
standard.  
 
5.2 Texture Analysis in Differentiating between 
Glioblastoma and Metastasis 
Glioblastoma and metastasis (MET) are the two most common types of brain tumor and 
both these of tumor types exhibit similar radiologic appearance on routine MR imaging10, 
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11. Differentiating between GBM and MET is very important because they have different 
biological mechanisms and require different treatment strategies. Many studies have 
focused on advanced imaging modalities12- 14 such as diffusion tensor imaging, perfusion 
MRI, spectroscopy, and perfusion CT for non-invasively differentiating between these 
two types of tumor. These advanced imaging modalities require long scan times, 
expertise in advanced imaging, and additional imaging modalities in the case of CT, 
which increases cost, examination time, and patient exposure to radiation. Since T1w 
imaging is part of routine brain tumor MRI examination, our technique utilizes easily 
accessible MR images and provides quantitative information without additional cost. In 
our current study (Chapter 3) we have shown that first-order texture feature of standard 
deviation and second-order texture features of entropy, inertia, homogeneity, and energy 
may be able to differentiate between the two groups. ROC curve analysis showed 
combining first- and second-order features increases the predictive accuracy in 
differentiating between GBM and MET. When used individually, the second order 
texture feature of inertia had the best predictive accuracy followed by homogeneity and 
energy. This study was the first attempt to quantify the texture appearance of the tumor 
and use it as an indicator in order to differentiate between GBM and MET. The simplicity 
of implementing our technique makes it more desirable than other advanced techniques. 
In future studies, various models can be created with combinations of these texture 
parameters. With further evaluation and validation of the models on a larger sample size, 
these models can be used in clinical settings to predict tumor types with routine MR 
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images. This would prevent needless tumor biopsies and cut down the imaging and 
ultimately examination time. 
 
5.3 Texture Analysis in Patient Selection for Radiation 
Therapy 
Helical tomotherapy (HT) is a radiation delivery technique that allows for a radiosurgery-
type simultaneous infield boost (SIB) of multiple brain metastases15, 16 synchronously 
with whole brain radiation therapy (WBRT) without separate stereotactic procedures. 
Patient selection is crucial since some patients’ tumors may not respond to HT type 
WBRT+SIB. In our current study (Chapter 4), as a first step toward the broader objective 
of developing a means for response prediction, we have demonstrated that smaller size 
lesions may respond better to this type of radiation therapy. We have also shown that 
measures of appearance provide limited added value for response prediction. Size 
measures have also been shown to be a good prognostic factor for the SRS type of 
radiation therapy17. Qualitative assessment of the lesions may also predict the success of 
the SRS type of radiosurgery18. None of these predictors have previously been studied for 
the WBHT + SIB type of radiation therapy. Our study was the first attempt to quantify 
the texture appearance of the lesions and use it as an indicator for the prediction of tumor 
response to the WBHT + SIB type of radiation therapy. The use of these predictive 
markers can help identify the groups of patients who would benefit from WBHT+SIB 
(responders) while sparing the non-responders who would not benefit so that the latter 
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may be treated with other therapies. For the responders, this type of radiation therapy 
may represent an effective and less invasive option compared to the traditional 
combinations of surgery, or radiosurgery combined with WBRT. Future work with a 
larger sample size will support further validation of our results. This will lead to the 
development of a per-lesion prediction of response approach based on pre-treatment 
MRI, which will support optimal treatment selection for patients with multiple brain 
metastases. 
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